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 i 
Abstract 
 
Prosthetic joint infection is devastating for the patient and costly to the 
healthcare provider. Key to the treatment of prosthetic joint infection is the 
identification of the causative organism. This can be challenging since biofilm 
encapsulated bacteria can establish themselves on the implant surface 
avoiding standard microbiological detection.  Focus, therefore has fallen on 
increasing the yield of bacteria from the explanted implant surface to make a 
diagnosis.  The marine nuclease NucB is a novel enzyme capable of digesting 
eDNA a component of the biofilm matrix, utilised by causal organisms in 
prosthetic joint infection. Use of NucB results in the release of bacterial cells 
from the biofilm, allowing them to be brought into planktonic suspension, 
thereby potentially aiding in their identification and the diagnosis of infection.  
To evaluate the potential of NucB to improve the diagnosis of prosthetic joint 
infection, a biofilm model was established initially using a microtiter plate 
system, then subsequently a series of simulated prosthetic implant surfaces 
using isolates of Staphylococcus epidermidis and Staphylococcus aureus. 
Finally, the ability of NucB to release bacteria from biofilms formed on 
explanted joint replacements from patients undergoing revision arthroplasty 
surgery was evaluated.  Results demonstrated that NucB produced a 
significant increase in the number of bacteria released when compared to 
controls and was, for the majority of isolates evaluated, comparable to 
sonication, another technique used to increase the yield of bacteria from 
prosthetic implant surfaces. Results from the evaluation of the explanted joint 
replacements demonstrated that NucB was comparable to sonication and also 
compatible with standard microbiological processing systems within the UK 
National Health Service. This has work demonstrated that NucB is effective 
at increasing the bacterial yield from biofilm encapsulated bacteria and has 
the potential to improve the accuracy of diagnosis in prosthetic joint infection, 
thus improving patient care.  
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1.  Chapter 1.  Introduction  
 
1.1. Osteoarthritis 
 
‘Life is movement, movement is life’ 
AO foundation 
 
The ability to undertake pain free movement is seen as an entitlement to younger 
generations. However, in later years the development of joint disease can limit activity, 
reduce mobility and affect the quality of life. Thus, the Swiss Orthopaedic 
Arbeitsgemeinschaft für Osteosynthesefragen (AO) foundation in 1958 adopted the 
motto ‘Life is movement, movement is life’ underlining the importance of mobility. 
While there are many causes of limited mobility one of the most common is 
osteoarthritis. 
Osteoarthritis is a debilitating and progressive disease affecting synovial 
musculoskeletal joints. The disease can affect almost all joints. However, those most 
commonly affected are hips, knees, ankles, hands and spine (Neogi and Zhang, 2013). 
The World Health Organisation (WHO) characterises osteoarthritis as loss of articular 
cartilage and progressive joint destruction. Although osteoarthritis primarily affects the 
joint articulation the disease pathology affects 9the surrounding tissues of the synovial 
joint including the synovium, ligaments, joint capsule and the muscles crossing the joint 
(Racine and Aaron, 2013). While the main trigger for the imbalance in the mechanical 
and biochemical properties within the joint that result in the development of 
osteoarthritis remain unclear, several risk factors for the development of the disease 
have been identified.  These include age, although sex, obesity, previous trauma, 
genetics and biomechanical alignment have all been demonstrated to contribute a 
degree of risk (Blagojevic et al., 2010, Palazzo et al., 2016). The ageing population and 
increased number of risk factors particularly obesity and sedentary lifestyle suggest that 
the incidence of osteoarthritis will increase over the coming decades (Zhang and 
Jordan, 2010, Birtwhistle et al., 2015, Culliford et al., 2015) 
The progressive nature of osteoarthritis means that as symptoms worsen patients seek 
referral to health care providers. Treatment options include non-operative management, 
including physiotherapy, with the aim of improving muscle function and stability 
across the joint, analgesia, titrated to pain following a recognised analgesic ladder. In 
addition, lifestyle modifications including altering roles at work and adaptations to 
accommodation such as grab rails and stair lifts.   These changes are often able to 
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provide a period of symptomatic improvement meaning that surgery may be delayed or 
not required (Filardo et al., 2016). However, given the nature of osteoarthritis, a 
significant portion of patients will fail to achieve symptomatic control without surgery. 
Having exhausted conservative treatment options for patients with symptomatic 
osteoarthritis of the hips and knees a number of patients will progress to total joint 
arthroplasty. 
 
1.2. Total joint replacement arthroplasty  
 
Total joint replacement arthroplasty involves the surgical excision of the degenerative 
joint surface and replacement with a synthetic material normally modelled on the 
excised joint. The aim is to replace the degenerative joint providing pain relief and 
improving function (Hussain et al., 2016). Modern total joint arthroplasty provides an 
effective management tool for osteoarthritis of the hips and knees. Surgical 
management has advanced significantly with the current design of the total hip 
replacement (THR) developed by Professor Sir John Charnley in the 1970’s remaining 
the ‘gold standard’ to which current joint replacement implants are compared 
(Charnley, 1970, Charnley and Feagin, 1973). While the majority of initial surgical 
interest focused on the total hip replacement, the development of the total knee 
replacement (TKR) followed a similar path. By the 1970s, designs were developed for 
the early cruciate retaining total knee replacements that resemble the modern TKR used 
today (Yamamoto, 1979).  
 
Patient related outcome measures have shown that hip and knee replacements are 
effective at reducing pain and improving mobility (HSC, 2016). As a consequence, the 
number of total joint replacements has been increasing steadily. In 2017 there were 
around 67,000 total hip replacements and 66,000 total knee replacements in the UK 
(NJR, 2017) resulting from an ageing population, increased life expectancy with the 
greater expectation of pain-free mobility in later life. Associated with an increase in the 
prevalence of known risk factors such as obesity, the incidence of osteoarthritis and 
therefore the expected demand for total joint arthroplasty in the UK and the developing 
world is expected to increase in the decades to come (Neogi and Zhang, 2013, Johnson 
and Hunter, 2014, Pilz et al., 2018). Thankfully, following decades of development, 
surgical management with hip and knee total joint arthroplasty is an effective treatment 
for symptomatic osteoarthritis. 
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1.3  Prosthetic joint infection (PJI) 
 
While the majority of patients will have an excellent outcome from joint replacement, 
a number of patients will experience complications, of these prosthetic joint infection 
(PJI) is one of the most devastating. Prosthetic joint infection is the clinical 
manifestation from the immune response due to microorganisms within the replaced 
joint (Zimmerli, 2014). The manifestation and development of PJI depends on a number 
of factors including the type of joint replaced, pathogenesis of the causal organism and 
systemic host factors of the patient (Tande and Patel, 2014). 
Rates of PJI are difficult to measure primarily due to variations in the quality of data 
collected (Tanner et al., 2013). Infection rates remain low affecting around 1 % of THR 
and 2 % of TKRs (Pulido et al., 2008). This increases to 5-12% for revision surgery 
(Mortazavi et al., 2010). The greatest risk period for the development of infection is up 
to 2 years following the index surgery where around 60-70% of infections occur (Pulido 
et al., 2008, Kurtz et al., 2010). Several risk factors are recognised for the development 
of PJI, Zhu et al in a systematic review and meta-analysis of 14 studies identified 31 
potential risk factors for PJI (Zhu et al., 2015).  Of these diabetes mellitus and 
rheumatoid disease were two of the most strongly associated systemic conditions 
increasing the risk of PJI with a combined odds ratio of the studies of 1.26 and 1.41 
respectively (95% Confidence interval). The effect of diabetes mellitus is multifactorial 
with established microvascular disease affecting wound healing leading to wound 
breakdown and subsequent PJI (Chun et al., 2014, Liu et al., 2017b). Secondarily poorly 
controlled perioperative hyperglycaemia has been demonstrated to dampen the immune 
response resulting in impaired immune function and an increase in the risk of PJI 
(Mraovic et al., 2011, Maradit Kremers et al., 2015). Rheumatoid arthritis is frequently 
managed with the use of disease modifying anti-rheumatic drugs (DMARDs) that 
modify the immune response to improve symptoms. As a consequence of the immune-
modulation, there is an increased risk of PJI after joint arthroplasty (Kawakami et al., 
2010). These systemic risk factors for PJI cannot be avoided, therefore focus has fallen 
on the optimisation of patient factors prior to surgery. For example, improving 
hyperglycaemic diabetic control prior to surgery (Agos et al., 2014, Yang et al., 2017).   
For rheumatoid patients, withholding of certain DMARDS prior to joint arthroplasty is 
recommended by the British Society for Rheumatology (Ding et al., 2010). 
As well as systemic conditions there are several perioperative risk factors that have 
been demonstrated to increase the incidence of PJI. Perioperative transfusion via its 
immunomodulatory effect has been demonstrated to increase the risk of PJI (Munoz et 
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al., 2005) as well as increased length of surgery has been demonstrated to increase 
infection risk. This may be a direct effect from a prolonged exposure of the joint or a 
surrogate marker for the complexity caused from another known risk factor such as 
obesity. Due to these confounding factors, attempts have been undertaken to develop a 
composite risk score. The National Nosocomial Infection Surveillance System risk 
score aims to aggregate the number and the influence of multiple risk factors both 
systemic and perioperative (Berbari et al., 1998, Aslam et al., 2010). A score of two or 
more has been associated with an increased risk of PJI (Moran et al., 2010) however, it 
is not frequently utilised in the UK.  While several attempts have been made to reduce 
infection rates, unfortunately some patients will still develop PJI following surgery and 
once established, it is helpful to further classify the type of PJI to guide management 
options.  
 
1.4  Classification of prosthetic joint infection  
 
To aid in the discussion, comparison and management of PJI several classification 
systems have been developed. The most simple but widely accepted of these was 
adopted by Zimmerli who divided infection into early, delayed and late categories in 
relation to the time of infection since surgery (Zimmerli et al., 2004). 
 
Early   within 3 months of implantation 
Delayed   3–12 months after implantation 
Late    more than 12 months after implantation 
 
 
Early infections are thought to start at the time of the procedure via direct inoculation 
into the joint by a virulent organism. These patients present with sudden onset joint 
pain, erythema and warmth at the implant site within the first few weeks of surgery. 
Delayed presentation is again related to direct inoculation but with a less virulent 
organism producing a lower grade infection with less systemic effects and with more 
subtle signs and symptoms such as persistent joint pain and intermittent joint swelling. 
Late infections occur via haematogenous spread from established bacterial infection 
distant from the joint. Haematogenous prosthetic joint infection is unrelated to the 
surgery and involves colonisation of the joint from another source of infection seen 
most commonly within 2 years of initial surgery (Bozic et al., 2010).  Sources of 
infection commonly include chest, genitourinary tract or dental surgery (Chen et al., 
2014).  
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Tsukayama et al divided PJI into four groups not solely based on the time since 
operation but also on the presumed mode of infection for hip and subsequently knee 
arthroplasty infections  (Tsukayama et al., 1996, Tsukayama et al., 2003).  Types 2-4 
included similar time scales for infection being early, delayed or late as well as a type 
1 infection relating to an unexpected positive culture result from a presumed non-
infected revision due to aseptic loosening.  A further classification system by 
McPherson et al  included features about the host as well as the mode of infection 
(McPherson et al., 2002). Infections are graded as type I, II, or IV, grade 2-4 being early 
postoperative infection, haematogenous infection, and late chronic of the Tsukayama 
classification as well as the systemic host status graded as A – Uncompromised, B – 
Compromised and C - Significant compromise. The limb is also graded with regards 
the soft tissue envelope associated with the implant that can be; 1 – uncompromised , 2 
- compromised, or 3 significantly compromised (McPherson et al., 1999, McPherson et 
al., 2002). Development of staging systems in PJI has helped both in the clinical 
management and in research, improving comparison between studies. These systems 
have improved clinical care resulting in a more individualised approach as well as the 
development of treatment strategies and prognostic information for these complex 
cases of PJI. 
 
1.5  Management of Prosthetic joint infection 
 
Successful management of PJI requires surgical intervention and antibiotic treatment 
and is best managed by a multidisciplinary team. Tande and Patel in their review article 
for prosthetic joint infection summarises effectively the goals of surgery (Tande and 
Patel, 2014) which are; “To eradicate the infection, restore pain free function of the 
infected joint, and minimise PJI related morbidity and mortality for the patient.” 
Treatment options vary and are often guided by the classification of the PJI. 
Debridement, antibiotics and implant retention (DAIR) is often attempted in the 
presence of early infection with well-fixed implants (Lora-Tamayo et al., 2013) 
(Bergkvist et al., 2016) The joint replacement is washed and debrided with exchange 
of the modular components that can easily be removed at the time of surgery. 
Subsequently the patient is treated with antibiotics for a period of time. This approach 
is often seen as favourable, being less destructive than a full revision. The outcomes 
from DAIR are dependent on several factors such as the antibiotic sensitivity of 
organism and host factors including liver cirrhosis predicting failure (Tornero et al., 
2014a). Thorough debridement is crucial with novel techniques such as the use of acetic 
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acid being evaluated to improve outcomes (Williams et al., 2017). Nevertheless, the 
outcomes following DAIR are variable with inconsistencies in the techniques and 
indications.  A recent retrospective review of 67 consecutive patients presenting with 
acute PJI following TKR demonstrated success of DAIR in 69 % of all patients. 
However when the resistant organisms were excluded such as methicillin-resistant 
Staphylococcus aureus (MRSA) and those with Pseudomonas aeruginosa the success 
rate improved to 85% (Duque et al., 2017). For certain patients with PJI DAIR is not 
an option and they often require revision of the joint.  This involves the complete 
removal of the implant, debridement and implantation of a new joint. This can be 
undertaken as a single stage procedure or with a time interval between removal of the 
infected joint and implantation, also known as a two-stage procedure.  A systematic 
review demonstrated no clear advantage over either approach (Beswick et al., 2012). 
However, a prospective randomised controlled trial currently recruiting will enable the 
comparison of both techniques and help guide future management (Strange et al., 
2016). Occasionally complex PJI is not amenable to further revision arthroplasty, and 
salvage procedures such as knee fusion in selected patients has achieved acceptable 
function (Razii et al., 2016). 
 
The complexity of management choices for surgical intervention is challenging and due 
to ongoing clinical research, is often evolving. This is summarised below in Figure one 
which shows the algorithm used within the Bone Infection Unit at Oxford BIUO– this 
provides insight into the approach undertaken within the UK (Moran et al., 2010). 
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Figure 1. Flowchart summarising the selection of an appropriate management strategy 
for an infected prosthetic joint, Nuffield Orthopaedic Centre, Oxford, UK.  
 
No matter which surgical strategy is undertaken the goals of surgical intervention 
remain the same. The debridement of infected tissue, explantation or exchange of 
modular components - depending upon the planned strategy -  and postoperative 
antimicrobial therapy to target any remaining infection.  
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1.6  Increasing challenge and outcomes of prosthetic joint infection  
 
While thankfully rare, the incidence of PJI is predicted to increase (Tande et al., 2014), 
this is related to a number of factors. Increasing demand for prosthetic joint replacement 
associated with an increasing life expectancy will play a significant role.  The last 15 
years have seen an increasing number of patients undergoing joint replacement and this 
trend is set to continue for hip and knee replacements with two studies predicting 
significant increases into 2030-5 in the UK and USA respectively (Kurtz et al., 2007, 
Culliford et al., 2015). Prosthetic replacements for other joints such as ankle 
replacements are less common. The National Joint Registry UK however, has 
demonstrated the practice is increasing rapidly (NJR, 2017). The life expectancy 
increase means that patients undergoing joint replacement will have increased 
residency of their joint. This increases the chance of haematogenous spread with late 
PJI set at 1% per year  (Huotari et al., 2015). Increasing life expectancy will therefore 
correlate with increased incidence of joint infection. Antibiotic resistance is also 
increasing with WHO and the United Nations both identifying emerging resistance as 
one of the greatest challenges facing modern day healthcare (The Lancet 
Gastroenterology Hepatology, 2016, Castro-Sánchez et al., 2016). Obesity as 
mentioned previously is also a known risk factor for infection, nationally the rates of 
obesity are increasing (Arroyo-Johnson and Mincey, 2016). As a consequence, rates of 
infection secondary to obesity are set to increase. Finally, clinicians are getting better 
at diagnosing infection in part due to their increased awareness of the underlying 
microbiology and secondarily in recent years by the development of new biomarkers 
that may prove more sensitive and specific for PJI (Deirmengian et al., 2014).  Overall 
these factors will likely result in the continued rise in prevalence of PJI as demonstrated 
by a recent analysis using National Joint Registry data by Lenguerrand et al. Using 
linked data from 2005-13 analysis demonstrated that the prevalence of revision due to 
PJI in the three months following primary hip arthroplasty increased  2.3 fold (95% CI 
1.3 to 4.1) and 3.0-fold (95% CI 1.1 to 8.5) following revision hip arthroplasty 
(Lenguerrand et al., 2017). 
 
Successfully managed patients with PJI and their clinicians face further challenges 
following the eradication of infection. Quality of Life measures are poorer compared 
to matched patients having undergone the same surgery without associated PJI (Helwig 
et al., 2014).  Patients undergoing revision surgery for PJI have an increased rate of 90-
day mortality compared to those revised for aseptic loosening (Zmistowski et al., 2013). 
PJI associated mortality is often underestimated with rates worse than cancer diagnosis 
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for prostate and breast. (Berend et al., 2013). As well as being devastating for the 
patient, the predicted increase in cases means PJI represents a costly and avoidable 
expense to healthcare providers. With patients requiring prolonged periods of inpatient 
hospital care, multiple hospital admissions and, if offered revision surgery, costly new 
revision implants.  In the USA by 2020 the cost burden due to PJI is expected to be 
$1.62 billion per annum (Kurtz et al., 2012). 
 
In summary, prosthetic joint infection is a problematic complication for the patient 
almost always requiring further surgery. Further surgery can be extensive, repetitive 
and is not without complications. Depending upon treatment options many patients 
have prolonged periods without a functioning joint and associated immobility. They 
may require long periods of antibiotic therapy in an attempt to clear infection. Incidence 
of PJI is increasing, costly and challenging problem for healthcare providers. For the 
patient PJI often represents a life-changing event associated with long term loss of 
expected function and increased risk to life. The aims of management are to provide a 
painless, functional and infection free joint replacement. Key to this is the diagnosis of 
infection and the identification of the causative organism. 
 
1.7  Diagnosis of prosthetic joint infection 
 
The approach to PJI diagnosis is to firstly confirm if the joint is infected, secondly 
identify the causal organism and subsequent antimicrobial sensitivity to guide further 
treatment. Currently there is no single diagnostic test that is 100% accurate for PJI 
diagnosis. Diagnosis requires a high index of clinical suspicion starting with initial 
history and examination, plain film radiographs, laboratory results from peripheral 
blood and synovial fluid from joint aspiration to attempt the isolation of  the causative 
organism (Osmon et al., 2013a). Since there is no single test that is able to confirm PJI, 
several diagnostic criteria have been established. The Infectious Diseases Society of 
America (IDSA) and the Musculoskeletal Infection Society (MSIS) both based in the 
USA, have published criteria for the diagnosis of PJI (Parvizi et al., 2011b, Osmon et 
al., 2013a). Within England, Public Health England (PHE) collect data on the reporting 
of surgical site infection including PJI using the Centre for Disease Control (CDC) 
definition (Horan et al., 1992). This is non-specific for PJI and therefore the MSIS 
criteria have frequently been adopted. The IDSA divide their classification into major 
and minor (Della Valle et al., 2010, Osmon et al., 2013b). Major criteria for joint 
infection of which one or other is considered diagnostic are either: 
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• Two positive periprosthetic cultures with identical organisms  
• A sinus tract communicating with the joint.  
Minor criteria where three conditions have to be met to be considered an infection: 
 
• Elevated serum C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR) 
• Elevated synovial fluid white blood cell (WBC) count OR ++change on 
leukocyte esterase test strip 
• Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%) - 
Positive histological analysis of periprosthetic tissue 
• A single positive culture 
 
The MSIS also have major and minor criteria: 
 
Major Criteria: 
• Sinus tract communicating with the prosthesis 
• An identical pathogen isolated by culture from at least two separate tissue or 
fluid samples obtained from the affected prosthetic joint 
Minor Criteria: 
• Elevated serum erythrocyte sedimentation rate (ESR) and serum C-reactive 
protein (CRP) concentration 
• Elevated synovial fluid leukocyte count 
• Elevated synovial fluid neutrophil percentage (PMN%) 
• Presence of purulence in the affected joint 
• Isolation of a microorganism in one culture of periprosthetic tissue or fluid 
• Greater than five neutrophils per high-power field in five fields observed from 
histologic analysis of periprosthetic tissue at x400 magnification. 
 
The development of these diagnostic criteria has aided both the clinical management 
and research into PJI. Although there are several classification systems available for 
use they are similar in their inclusion criteria, with work demonstrating high 
concordance in PJI diagnosis (Melendez et al., 2013). Whichever system is utilised both 
systems place heavy credence on intraoperative culture techniques. Using the above 
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guidance whichever criteria are used PJI can be easy to diagnose. This is more often 
the case in early infections or when the patient presents systemically unwell with fever. 
However, identification of the organism can often be problematic or impossible 
especially if the presentation is related to a chronic low-grade infection with no 
systemic symptoms or if antibiotics have been prescribed prior to investigations, since 
antibiotics kill the more easy to culture planktonic bacteria, reducing the likelihood of 
recovering viable bacterial cells from tissues samples or synovial fluid aspiration 
(Osmon et al., 2013a). These patients therefore represent a significant challenge. 
Incorrectly assuming that either the revision joint surgery is not infected or that the 
infection has been successfully treated as part of a two stage procedure meaning that 
patients may receive inadequate and suboptimal treatment, increasing their risk of 
subsequent failure and further surgery (Nelson et al., 2014, Jacobs et al., 2017) This 
group of patients are designated as having culture negative prosthetic joint infections 
(Berbari et al., 2007). When faced with the possibility of culture negative prosthetic 
joint infection by definition, the challenge of identification of the causal organism is 
increased or impossible. This phenomenon of a culture negative joint infection can be 
explained in the context of a biofilm-associated infection. 
 
1.8     Biofilms and their role in prosthetic joint infection  
 
Bacteria are known to exist in two distinct forms, planktonic and sessile (McDougald 
et al., 2012).  Planktonic bacteria lead an individualised existence and are motile, fast 
dividing and usually promote a potent immune response (Hall-Stoodley et al., 2004). 
Planktonic bacteria subsequently received much of the early attention of 
microbiologists, being responsible for epidemics that drove the development of the 
modern antibiotic era. Conversely, sessile bacteria live within a community, share 
resources, communicate and are protected within a matrix known as a biofilm. William 
Costerton and colleagues were the first to recognise the association of chronic 
infections and biofilm encapsulated sessile bacteria (Costerton et al., 1978) describing 
biofilms as “a structured community of bacterial cells enclosed in a self-produced 
polymeric matrix and adherent to an inert or living surface”. Biofilms therefore are a 
community of bacteria and/or fungi surrounded by a slime like matrix produced by the 
organisms that offers a protective environment within which cells can resist antibiotic 
concentrations up to 1000 times the Minimal Inhibitory Concentration (MIC) (Donlan, 
2000). Biofilms are found in around 65% of clinical infections in the developed world 
(Center for Disease Control). The development of biofilms can be divided into four 
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stages. Initial cell adhesion, aggregation, maturation and subsequent dispersal. 
Common surfaces used in joint replacement such as cobalt-chrome alloys, titanium, 
stainless steel, polymethyl-methacrylate (PMMA) cement and high molecular weight 
polyethylene (HMWPE) have all been shown to act as surfaces for biofilm formation 
(Rochford et al., 2012). This process occurs quickly with Gristina labelling the process 
as the “race to the surface” (Gristina, 1987).  This represents the short period of time 
following the implantation of the new prosthetic joint replacement and the colonisation 
of the implant with either host cells or bacteria that may be present at the time of 
surgery. Key to understanding the formation of the biofilm is understanding its life 
cycle.  
 
1.8.1 Life cycle of biofilms 
 
Figure 2. Classic understanding of biofilm formation P. Dirckx, Center for Biofilm 
Engineering, Montana State University, Bozeman 
 
 
Individual planktonic bacteria are mobile and migrate to prosthetic surfaces via 
electrostatic and hydrostatic forces, cell adhesion starts within a few seconds of 
implantation of the prosthetic joint. Many bacteria are known to produce adherence 
proteins for initial attachment. The initial attachment is progressive and reversible 
(Garrett et al., 2008). Cellular aggregation follows with activation of genes prompting 
the proliferation of extra cellular matrix producing a recognised early biofilm that can 
colonise a surface (Costerton et al., 1999). Communication via quorum sensing allows 
the coordinated maturation of the biofilm (Yarwood et al., 2004). Maturation of the 
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biofilm allows stabilisation of the matrix which develops into a complex 3-D structure. 
Following maturation, the biofilm can release planktonic cells. These cells are motile 
and are able to travel to distance sites and adhere to new uncolonised surfaces, repeating 
the process (Costerton et al., 1999, Stoodley et al., 2002). Bacteria that are able to form 
biofilm-associated colonies have a number of advantages compared to their planktonic 
counterparts and it has been suggested that the more sessile nature could represent the 
preferred form of existence. (McDougald et al., 2012). The biofilm encapsulated 
organisms benefit from the defensive capabilities of the biofilm matrix with it primarily 
acting as a barrier protecting the organism from antimicrobial compounds, bactericidal 
agents, shear stress forces and phagocytic clearance by the host immune system 
(Jefferson, 2004). The extracellular matrix is also able to pool resources for the 
encapsulated organisms including carbon, nitrogen and phosphate, all key nutritional 
components for bacterial cell life (Beveridge et al., 1997). Antibiotic resistance 
provided by the bacteria is multifactorial. The biofilm matrix can act as a physical 
diffusion barrier preventing antibiotic penetration to the deeper embedded cells. While 
the altered environment including a lower pH has also been shown to reduce the 
effectiveness of certain antibiotics towards bacterial cells within the biofilm (Donlan, 
2000). Some of the protection afforded to sessile biofilm encapsulated bacteria relates 
to its structure.  
 
1.8.2 Structure of biofilms 
 
The structure and composition of the extra cellular matrix varies between bacterial 
species and within strains of the same species. Even within the same strain, 
environmental factors including availability of nutrients or shear stresses affect biofilm 
development (Branda et al., 2005). However, key structural components are similar and 
include polysaccharides, proteins and extracellular DNA (eDNA) (McDougald et al., 
2012). 
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Figure 3. Complex structure of bacterial biofilm matrix demonstrating key 
components and metabolic activity (McDougald et al., 2012). 
 
1.8.3. Extracellular DNA (eDNA) and its role within the biofilm matrix 
 
  The role of Extracellular DNA in biofilms was first noted by Catlin et al in 1956 
(Catlin, 1956). This work initially received little attention and eDNA was not studied 
as much as other better known biofilm constituents such as proteins and 
polysaccharides. eDNA was thought to be irrelevant, a waste product of the biofilm. 
However, Whitchurch et al showed that DNase-1 was effective at dispersal of 
Pseudomonas aeruginosa biofilms (Whitchurch et al., 2002) and since then numerous 
papers have highlighted the important role of eDNA in biofilm stability (Montanaro et 
al., 2011, Jakubovics et al., 2013, Okshevsky and Meyer, 2014, Ibanez de Aldecoa et 
al., 2017). Varying mechanisms exist for the release of eDNA from the biofilms of 
different microorganisms. These include active secretion  seen in Pseudomonas 
aeruginosa (Schooling et al., 2009) or by cell lysis, as seen in Staphylococcus 
epidermidis and Staphylococcus aureus. Work by Qin et al  in 2007 noted that the 
release of Staphylococcus epidermidis eDNA was related to autolysin AtlE-mediated 
cell lysis. AtlE has an autolytic activity resulting in a subpopulation of bacteria lysing, 
releasing DNA and thus promoting biofilm formation for the remaining bacteria. The 
DNA released was identical to chromosomal DNA and inactivation of atlE reduced 
DNA release by more than 90% in the isolates tested (Qin et al., 2007). Other 
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Autolysins may play a role in cell lysis and the triggering of release is thought to be 
controlled by quorum sensing within the colony. This fratricidal cell death has been 
observed in other bacteria including Staphylococcus aureus mediated through the 
activity of murein hydrolases, encoded by the atl and lytM genes producing altruistic 
cell death (Thomas et al., 2009, Mann et al., 2009).  
 
Within the biofilm eDNA has several important and distinguishable roles (Okshevsky 
and Meyer, 2015, Vorkapic et al., 2016). One of the primary roles is structural support 
providing a key component to the mechanical stability of the biofilm. DNA is well 
suited to this role being a relatively stable molecule with Peterson et al  highlighting 
the role of eDNA in the viscoelasticity of the biofilm and the ability of the matrix to 
withstand mechanical deformation (Peterson et al., 2013).  Since biofilm constituents 
are known to vary with environmental factors, it could be postulated that biofilms 
within these environments may have a higher eDNA component. Part of the structural 
role of eDNA is its ability to bind to itself and other constituents of the of extra cellular 
matrix thus increasing its stability. This includes DNA binding proteins released by 
bacteria including integration host factor a DNA-binding protein capable of linking 
eDNA strands (Brockson et al., 2014). EDNA is capable of interacting with 
polysaccharides, another component of the extra cellular biofilm matrix, increasing its 
stability (Okshevsky et al., 2014). As well as interacting with other constituents of the 
biofilm matrix, eDNA can also bind directly with the bacterial cell wall via surface 
proteins recently demonstrated within meningococcal biofilms (Arenas et al., 2013). 
As well as its important structural and mechanical properties of eDNA can act as a 
nutritional store, is a mechanism for genetic exchange and can add to antibiotic 
resistance by its ability to bind to positively charged antibiotics such as 
aminoglycosides (Das et al., 2013). eDNA importance has also been highlighted in 
mixed species biofilms particularly Staphylococcus epidermidis and Candida albicans 
(Pammi et al., 2013). Furthermore, bacterial strains with decreased levels of eDNA in 
their biofilm have been shown to be easily dispersed.  Rice et al has demonstrated that 
a Staphylococcus aureus mutation in the cidA gene which codes for a murein hydrolase 
regulator. Plays an important role in cell lysis and subsequent eDNA release. In mutant 
strains biofilm had significantly reduced amounts of eDNA and demonstrated weaker 
biofilm morphology and adherence (Rice et al., 2007). The opposite affect was seen by 
modulation of the lrgAB operon by Mann et al promoting cell lysis and subsequent 
biofilm formation in Staphylococcus aureus (Mann et al., 2009). 
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Although recognised many years ago as being part of bacterial biofilms, only in recent 
years has eDNA been thought of as a potential target for therapeutic intervention. Since 
eDNA forms part of the biofilm produced by several bacteria commonly seen in 
prosthetic joint replacement, an anti-eDNA approach seems an attractive target for 
biofilm control (Montanaro et al., 2011, Okshevsky et al., 2014). This includes the use 
of nucleases to disrupt the eDNA component of the biofilm formed in PJI  to aid in the 
diagnosis of infection from the implant surface as well as other techniques to increase 
yield. 
 
1.9 Improving diagnostic microbiological tests for PJI 
 
One of the most important techniques to improve the diagnosis of PJI is to increase the 
yield from explanted prosthetic implant surfaces by disrupting the biofilm matrix. 
These techniques have the advantage of providing a causal organism, which can be 
tested for antibiotic sensitivity and therefore guide antimicrobial management. Since 
biofilm encapsulated organisms are known to form freely on prosthetic implant surfaces 
(Costerton et al., 1978, Neut et al., 2003) which are often exchanged at the time of 
surgery. These implants if evaluated for the presence of biofilm encapsulate microbes 
can provide important addition information that is often overlooked.  
 
1.10   Techniques to increase the yield of bacteria from Prosthetic implant surfaces 
 
The use of sonication to aid the diagnosis of prosthetic joint infection was initiated by 
Trampuz et al (Trampuz et al., 2007). Sonication utilises ultrasonic energy which 
generates a rapid change in pressure on the surface of prosthetic joint replacements 
which dislodges attached microorganisms. The technique requires the explanted 
prosthesis to be transported from the operating theatre to the microbiology laboratory 
in a sterile fashion. Although techniques vary, a recognised technique uses a period of 
vortexing and then sonication for 5 minutes, followed by additional vortexing of the 
prosthesis.  The resulting sonicated fluid is then processed using standard culture 
techniques (Trampuz et al., 2007). 
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Figure 4. Sonication technique demonstrating the votexing and sonication steps 
required for processing samples (Trampuz et al., 2007). 
 
Results of a meta-analysis of 12 papers have shown that sonication provided a 
combined sensitivity of 0.80 and specificity 0.95 (Zhai et al., 2014).  The use of 
sonication was therefore more effective than standard tissue culture techniques within 
this analysis (Zhai et al., 2014). Sonication has been shown to be especially helpful 
when used for patients that have been on antibiotic therapy within 14 days of sampling 
(Trampuz et al., 2007). This supports the rationale that while planktonic bacteria may 
have been affected by antibiotics given around the time of revision, the bacteria present 
within a biofilm matrix established on the implant surface are protected due to the 
higher antibiotic concentrations required to kill them. These however, are not isolated 
by standard sampling techniques providing a false negative result. Sonication has been 
shown to provide faster culture and sensitivity results than standard culture methods 
(Zhai et al., 2014). Sonication has also been used to augment other diagnostic 
techniques such as polymerase chain reaction (PCR) and certain microcalorimetry 
techniques (Borens et al., 2013, Renz et al., 2018). However, sonication has a number 
of limitations that have prevented it being widely adopted outside of research centres. 
Explanted prostheses are large, difficult to handle and transport in a sterile fashion. 
Initial work with sonication was associated with contamination of the cultures 
providing false positive results (Trampuz et al., 2006). Some studies were unable to 
process all of the explanted prosthesis due to size especially revision implants or mega 
prothesis. Therefore, sonication could not be utilised for the most high-risk cases where 
the correct identification of causal organism is paramount. The samples require 
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specialist equipment and skills not available in most microbiology laboratories. The 
technique is time consuming, requiring several steps and processing in a laminar flow 
hood.   Prolonged or high-energy sonication is also known to kill bacteria (Monsen et 
al., 2009). Although optimal levels of sonication have been identified for diagnostic 
analysis, the potential for inadvertent bactericidal effects remain, reducing the 
likelihood of a successful culture identification. Fungal joint infection is rare and often 
difficult to diagnose. To date, sonication has not be validated for fungal infections.  
Finally, there is a risk that sonication of antibiotic cement may cause release of 
antibiotics which kill the very cells that need to be cultured for diagnosis (Hendriks et 
al., 2003).  
 
Therefore, the Infectious Diseases Society of America suggest that explanted prosthesis 
can be submitted for sonication recognising that ultrasonicate can improve the 
sensitivity of aerobic and anaerobic culture compared to traditional tissue culture 
(Osmon et al., 2013a). However complications have meant that sonication is not 
currently recommended for routine use by the International Consensus on 
Periprosthetic Joint Infection 2013 (Parvizi et al., 2013). 
“We do not recommend routine sonication of explants. Its use should be limited to cases 
of suspected or proven PJI (based upon presentation and other testing) in which 
preoperative aspiration does not yield positive culture and antibiotics have been 
administered within the previous 2 weeks. 
 
Delegate Vote: Agree: 84%, Disagree: 9%, Abstain: 7% (Strong Consensus)” 
 
The Microbiology Investigations UK Standards guidance for the investigation of 
prosthetic joint infection samples is currently under review but recommends that 
sonication should be used only as a research tool and not for routine practice. (B44, 
2017) 
 
While sonication has proven effective and is most widely utilised to increase culture 
yield from the explanted implant surface there are other techniques available. These 
include the use of chemical agents such as Dithiothreitol (DTT). DTT is a strong 
reducing agent used in microbiology laboratories for liquefying specimens from the 
respiratory tract by cleaving disulfide bonds present within the mucus (Guiot et al., 
2017) One laboratory and two clinical studies have shown that DTT is equivalent to 
sonication at identification of causal organisms from the implant surface of explanted 
joints (Drago et al., 2012, Drago et al., 2013). This technique is not widely practiced 
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but has recently been commercialised as MicroDTTect (Microdttect)  with a recent  
independent evaluation in a clinical series of 232 patients undergoing revision joint 
surgery. Overall DTT treatment was able to demonstrate comparable results to 
sonication (Sambri et al., 2018). To date sonication seems the most effective method of 
increasing yield from prosthetic surfaces of explanted joint replacements. However, 
several reasons have led to the technique not being widely introduced. Potentially an 
enzymatic approach may provide a solution in releasing bacteria from the implant 
surfaces.  
 
1.11. Nucleases and their potential role in releasing biofilm encapsulated bacteria 
via digestion of eDNA  
 
Nucleases are a group of enzymes capable of the hydrolysis of phosphodiester bonds 
of nucleotide subunits seen in nucleic acids. Thus, nucleases are capable of digesting 
eDNA which is known to form part of the biofilm matrix.  The use of nucleases in 
medicine has a long and successful history, most notably in the management of Cystic 
Fibrosis, a condition associated with chronic biofilm associated lung infections. Here 
once daily nebulised recombinant human deoxyribonuclease (rhDNase) is used as a 
mucolytic capable of reducing the viscoelasticity of sputum and enhancing the 
clearance of secretions (Suri, 2005). Although effective in Cystic Fibrosis  rhDNase, 
which is currently produced in  genetically engineered hamster ovarian cells is 
expensive primarily due to the low yields achieved,  thus potentialy, limiting its wider 
usage outside of therapeutics   (Ferrari et al., 1998, Okshevsky et al., 2014). However, 
nucleases are abundant in nature and several non-mammalian nucleases have been 
identified. Their secretion has been linked with the dispersal of several bacterial 
biofilms to assist in sporulation as well as to allow bacterial species to digest the eDNA 
component of the biofilm matrix as a nutritional store. (Mishra, 2002, Mann et al., 2009, 
Palchevskiy and Finkel, 2009, Vorkapic et al., 2016) 
 
 
1.12 Marine Nuclease NucB 
 
The action of deoxyribonuclease was first identified in 1978 by Akrigg and Madelstam 
in the marine organism Bacillus subtilis being most active during the late stages of 
sporulation (Akrigg and Mandelstam, 1978). Elevated levels stimulated by manganese 
release were shown to cause sporulation with self-induced degradation of the biofilm 
matrix to enable release of planktonic bacteria. Later Nijland et al recognised a 
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sporulation specific extra cellular nuclease while observing marine biofilms. The 
supernatant of Bacillus licheniformis EI-34-6 was capable of dispersing bacterial 
biofilms (Nijland et al., 2010). The enzyme subsequently was isolated and purified by 
the same group. Since the discovery of the marine nuclease NucB several advantages 
have been identified compared to other nucleases (Burgess et al., 2017). The production 
of large quantities of the secreted enzyme have been optimised by, Ragarajan et al 
allowing the scale NucB production providing cost-effective expression systems of 
NucB (Rajarajan et al., 2013). This production method is significantly cheaper 
especially if utilised within a  commercial scale production Bacillus fermentations (de 
Souza Vandenberghe et al., 2016), when compared to those requiring a mammalian line 
cell. Further evaluation has  demonstrated that compared to other nucleases NucB is a 
robust and relatively small protein (∼12 KDa) around half the size of human DNase I 
that can potentially penetrate the biofilm matrix more efficiently for eDNA degradation 
(Basle et al., 2018). The same group demonstrated that NucB is a non-specific 
endonuclease capable of the digestion of several sites of both single and double 
stranded and DNA substrates rather than the more limited nuclease enzymes. In 
addition NucB  demonstrated increased thermal stability  compared to DNase I when 
increasing its commercial application. 
 
 
Figure 5. A model of the interaction of Bacillus licheniformis NucB with DNA (Basle 
et al., 2018) 
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Finally work undertaken by Nijland et al has demonstrated that NucB was better 
adapted for bacterial biofilm dispersal than bovine rhDNase I  (Nijland et al., 2010). 
Following this Shakir et al utilising NucB demonstrated that it was able to disperse 
complex well-established mixed species biofilms from tracheoesophageal speech 
valves (Shakir et al., 2012). Mann et el demonstrated that nucleases were effective at 
the disruption of early biofilms established by Staphylococcus aureus however, less 
effective in more established biofilm colonies (Mann et al., 2009). Overall however, 
the nuclease degradation of biofilms has been evaluated on over 35 primarily bacterial 
species including both gram positive and negative bacteria as well as eukaryotic 
microbes including Candida albicans (Okshevsky et al., 2014), with several of these 
microbes being known causal agents in PJI (Aggarwal et al., 2014). 
 
As a result of the increased understanding of the importance of biofilm associated PJI, 
with the unique properties of NucB and with the ubiquitous presence of eDNA in 
microbial biofilms. Associated with the developing recognition of the importance of 
eDNA in the structure of biofilms and the with limitations in existing techniques to 
disrupt the biofilm matrix form the implant surface.  The potential of NucB to improve 
the diagnosis of prosthetic joint infection by releasing biofilm encapsulated bacteria via 
it action of eDNA is an appealing clinical target and will be evaluated in this work. 
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Aims and objectives 
 
 
The overall aim of this work is to evaluate the use of NucB to assist in the diagnosis of 
prosthetic joint infection by disrupting biofilm encapsulated bacteria from the implant 
surfaces. Allowing the liberated less dormant planktonic bacteria to be identified by 
culture techniques improving the diagnosis of infection and the management of 
prosthetic joint infection.  
 
The initial objective is to establish if NucB can effectively release biofilm encapsulated 
bacteria formed by reference strains and clinical isolates recruited from PJI in a 
microtiter plate model.  
 
Subsequently, utilising a simulated implant surfaces model to more closely replicate a 
prosthetic joint infection. The effect of NucB will be evaluated on bacterial biofilms 
established on these implant surfaces and evaluated against sonication.  
 
Finally, to establish if NucB can successfully increase the yield of microorganisms from 
the explanted prosthetic joint replacements recruited from patients undergoing revision 
surgery.  Comparing both NucB and sonication techniques as well as  evaluating the 
compatibility of NucB into the standard microbiology processing within the NHS. 
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2. Chapter 2. An in vitro model for assessing the efficacy of NucB in releasing 
bacteria from biofilms of clinically relevant bacteria 
 
2.1. Introduction 
 
Diagnosis of prosthetic joint infection is challenging, this in part is related to 
the ability of bacteria to produce a biofilm matrix on the implant surface, which protects 
the bacteria allowing them to avoid detection.  Consequently, the implant, which is 
frequently explanted at the time of revision surgery, often has biofilm encapsulated 
bacteria colonising its surface. Once released from this biofilm, the bacteria could be 
cultured and identified confirming the diagnosis of infection and guiding patient 
management. The marine nuclease NucB is capable of digesting eDNA which is known 
to form part of the bacterial biofilm matrix. This enzyme has the potential to degrade 
the biofilm matrix established on the implant surface releasing the encapsulated 
bacteria and allowing them to be identified by standard culture techniques used within 
the NHS. To appraise the potential of NucB to assist in the diagnosis of prosthetic joint 
infection an in-vitro model plate system was utilised allowing initial evaluation.  The 
first task was to acquire both clinical isolates and reference strains of bacteria for the 
in-vitro model. Staphylococcus aureus and Staphylococcus epidermidis, were recruited 
since combined  they are the most common causative organisms isolated from 
prosthetic joint infections accounting for 50% to 60% of infected total joint arthroplasty 
(Pulido et al., 2008, Tande and Patel, 2014, Hickson et al., 2015).  Following the 
recruitment of bacterial isolates their ability to form a biofilm on synthetic surfaces was 
evaluated.  This is a prerequisite for their use in the biofilm model. This assessment 
was undertaken using confocal laser scanning microscopy (CLSM). CLSM is an 
established technique used to evaluate the formation of biofilm from the chosen isolates 
(Schlafer and Meyer, 2016). This technique provides an insight into the nature of 
biofilms without disturbing their complex structure. The availability of fluorescent dyes 
can also be utilised to evaluate the presence of eDNA. Several stains are capable of 
interacting with DNA however, in order to stain the eDNA component of the biofilm 
the stains need to be impermeable to the cell membrane to avoid staining the 
intracellular DNA which does not form part of the biofilm matrix.  An evaluation of 
the eDNA fluorescent stains demonstrated that intercalating cyanide fluorescence dyes 
provided the best choice for evaluation of eDNA in the extra cellular matrix (Schlafer 
and Meyer, 2016). These cyanide dyes have high affinity to DNA and  are cell-
impermeable and develop over a thousand-fold increase in its green fluorescence when 
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bound to DNA (Larsson et al., 1994).  The cyanide dye YO-YO-1 was employed to 
confirm the presence of eDNA in the bacterial biofilm confirming a target for nuclease 
activity on the biofilm matrix.  
 
Having chosen the bacterial strains and confirmed their ability to form biofilm, the 
optimal growth media composition was established. This is important since the 
availability of nutrients can influence the growth rate of bacteria and subsequent biofilm 
production. Increased biofilm production has been demonstrated in low nutrient 
conditions, this phenomenon as a result of restricted growth media is known as the 
‘stringent response’ and would encourage bacteria to form a protective biofilm 
community in a poor nutritional environment as a means of preservation (de la Fuente-
Nunez et al., 2014, Strugeon et al., 2016). Evaluating and optimising the growth media 
concentration will ensure the abundant and constant biofilm for evaluation of NucB 
activity. The ability of the nuclease NucB to be used as a diagnostic tool requires certain 
enzyme characteristics. Firstly, the nuclease should be an effective and stable enzyme. 
Secondly, that the presence of NucB is non-cytotoxic or inhibit bacterial growth which 
is required for culture and identification. To determine this, the activity of NucB was 
evaluated and the ability to digest a quantifiable amount of calf-thymus DNA as a 
substrate. This was calculated both using gel-electrophoresis and mass-spectrometry. 
To determine the effect that the presence of NucB may have on bacterial cell growth, 
bacterial cultures were exposed to NucB and the rates of cell division determined by 
changes in optical density and the quantification of colony forming units over time.  
 
Lastly the effectiveness of NucB on the release of biofilm encapsulated bacteria on the 
chosen isolates was evaluated. This was initially a simple in-vitro model using a 
microtiter polystyrene plate. While this synthetic surface is not used for prosthetic joint 
replacement it provides a reproducible and manageable surface. The release of bacterial 
cells was quantified by calculating the colony forming units from the supernatant and 
from the optical density staining of the solubilised residual biofilm stained with crystal 
violet (Peeters et al., 2008). 
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Overall the objectives of this chapter are 
 
1. To obtain both clinical isolates of bacteria from NHS patients undergoing 
investigation or surgery for prosthetic joint infection and reference strains of the 
same species of bacteria from national collections.  
2. To optimise their growth conditions in vitro and to evaluate their ability to form 
a biofilm in a reproducible static in-vitro model.  
3. To determine if these isolates utilise eDNA as part of their biofilm and therefore 
have the potential for nuclease (NucB) degradation of the matrix.  
4. To evaluate the effectiveness of NucB to digest biofilm eDNA and consequently 
to release biofilm encapsulated bacteria by disrupting the biofilm matrix. 
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2.2. Materials and Methods 
 
2.2.1. Isolation and identification of clinical bacterial isolates utilised in in-vitro       
biofilm model.  
 
Clinical isolates were sourced from the Newcastle upon Tyne Hospitals NHS 
Foundation Trust. The clinical microbiology department from the trust were contacted 
and supplied clinical isolates from implant associated infections. Once identified by 
MALDI-ToF mass spectrometry (Gaudreau et al., 2018) at Newcastle upon Tyne 
Hospitals NHS Foundation Trust, samples were established on agar slopes for transfer 
to Newcastle University. Samples were inoculated into tryptic soy broth (TSB) and 
incubated overnight at 370C. Samples were then centrifuged to make a pellet before 
resuspension in TSA and creation of a glycerol stock for storage at -800c.   
 
2.2.2. Sourcing of bacterial reference strains utilised in in-vitro biofilm model.  
 
Reference strains were sourced from the National Collection of Type Cultures (NCTC).  
Staphylococcus aureus strain 6571 was deposited in the NCTC in 1944 and remains the 
clinical isolate used for the evaluation of clinical diagnostic microbiology laboratories 
serving as a reference strain for antimicrobial susceptibility evaluation (Heatley, 1944). 
The reference strain Staphylococcus epidermidis NCTC 11047 reference strain was 
isolated from the nasal cavity. It is used for evaluation of antibiotic sensitivity in 
research laboratories (Piddock and Zhu, 1991, McLaws et al., 2008). 
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2.2.3. Optimisation of growth media for bacterial biofilm formation. 
 
To identify the optimal concentration of TSB (Sigma-Aldrich, Dorset, UK) the 
following experiments were undertaken.  Each clinical isolate and reference strain was 
established from glycerol stocks on to TSA plates and statically incubated over night at 
37 0C. Representative colonies were chosen and inoculated into 5mls of sterile TSB and 
again incubated over night at 37 0C. TSB media was reconstituted as per manufactures 
instructions and was diluted as required with distilled water to produce final 
concentrations of 100%, 50%, 20% and 10% before autoclave sterilisation. The 
overnight TSB samples were centrifuged at 14,000 rpm for 10 minutes and then 
suspended in 5ml of 10% TSB. Using a spectrophotometer, the absorbance at 600 nm 
each media concentration was then inoculated with the re-suspended culture to create 
an optical density of 0.01 using unconditioned media of each concentration to measure 
background absorbance. Having established each media concentration with set 
inoculum, 180μL were added in triplicate wells to a sterile 96-well plate (Greiner Bio-
One). Appropriate blanks of media for each concentration were included. Samples were 
incubated statically overnight at 370C. To quantify biofilm formation, liquid medium 
was aspirated from the plate and each well was washed with sterile isotonic phosphate 
buffer (PBS) three times to remove non-adherent cells and samples were allowed to 
dry. Biofilm formation was quantified by staining with 200μL 0.1 % (w/v) crystal violet 
(per well). After incubating for 15 minutes at room temperature (20-25°C) the wells 
were washed gentle three times with PBS and allowed to dry.  The residual stained 
biomass was solubilised in 200μL 7 % acetic acid (v/v) and the A570 was read in a 
microplate reader (Synergy HT). The un-inoculated media acting as blanks were stained 
and washed in a similar fashion and the reading subtracted from sample absorbance 
values (Christensen et al., 1985). 
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2.2.4. Characterisation of biofilm formation with Confocal Laser Scanning 
Microscopy (CLSM) 
 
To evaluate and characterise the ability of the clinical isolates and reference strains to 
form biofilms containing eDNA each isolate was recovered from glycerol stocks on to 
TSA plates and statically incubated over night at 37 0C. Representative colonies were 
chosen and inoculated into 5mls of sterile TSB and incubated over night at 37 0c. The 
resultant stock culture was used to create an inoculum of 0.01 (O.D. A600) using sterile 
TSB. Sterilised 13mm glass cover slips were placed into a sterile six well tissue culture 
plates and covered with 3 mls of inoculum wrapped in para-film. The plates were then 
incubated statically at 37 0C for 24 hours. Following incubation, the liquid medium was 
aspirated from each well and the coverslips stained prior to microscopy. Both stains 
Y0-Y0-1 and Nile Red (Sigma-Aldrich, Sigma-Aldrich Company Ltd, Dorset UK) 
were reconstituted as per manufacturing instruction. The slides were covered with YO-
Y 1 for 15 minutes at room temperature in the dark. Following this the cover slips were 
stained with Nile Red Sigma-Aldrich, Sigma-Aldrich Company Ltd, Dorset UK) and 
again incubated in room temperature for 30 minutes. Excess stains were removed, and 
the slides transferred from the six well plates and mounted on microscope slide using a 
prepared well filled with PBS. Samples were kept in the dark for transfer for CLSM. 
Imaging was undertaken using the Nikon AR1 CLSM (Newcastle University Bio-
imaging Unit) with visualisation of Nile Red (excitation 549 nm, emission 428 nm), 
and Y0Y0-1 (excitation 491 nm, emission 509 nm) (Barnes et al., 2012). The acquired 
stacks of image were further analysed using 3D imaging software (Imaris, Bitplane)  
 
2.2.5. Sourcing and characterisation of NucB nuclease utilised for biofilm 
disruption.  
 
NucB was supplied by the Newcastle University Protein and Proteome Analysis 
department (NUPPA) and stored locally at -800C.  To minimise the effect of freeze 
thawing the enzyme was divided into aliquots required for individual experiments in 
2ml eppendorfs. To evaluate the enzyme activity and stability a series of experiments 
were conducted to compare the variation of activity between enzyme batch and effect 
of storage over time. Calf thymus DNA (Sigma D1501 - 1G) was utilised as substrate 
with effect of NucB being quantified by enzyme digestion. The early part of the reaction 
was evaluated using agarose gel electrophoresis. This technique was employed since 
perchloric acid used for the solubilisation of DNA is unable to solubilise larger base 
pair units. Once DNA digestion is established the later part of the reaction was 
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quantified spectrophotometrically. Standard assay conditions used for the evaluation of 
enzyme activity were as follows: 125μL of Tris Buffer 50mM Tris (pH8.0), 12.5 μL 
5mM MnSO4. (Stock 100mM) and 95.65 μL Sterile distilled water was reconstituted 
and added to 125μg Calf thymus (CT) DNA and 5 ng NucB creating a final reaction 
volume of 250μl. Having created the reaction mixture from stock solutions 125μg of 
calf thymus (CT) DNA from a 2mg/ml stock solution was reconstituted and stored as 
per manufacturing guidelines. These were mixed and pre-equilibrated at 37oC for 10 
minutes in a sterilised 2ml eppendorf. The reaction started by the addition and of 1.25 
μL NucB of a Stock 1μg/ml followed by further incubation at 37oC. To act as a control 
a no enzyme assay was included with the volume was made up with buffer solution. 
Incubation time intervals of 15 minutes, 30 minutes and 60 minutes were taken. For 
analysis by agarose gel (0.8% w/v) electrophoresis 50μl of the reaction was halted by 
the addition and mixing of 50 μl of phenol/chloroform/isoamyl alcohol mix for both 
enzyme and control. The mixture was shaken forming emulsion and  centrifuged at 13k 
rpm at 4oC for 3 mins in a benchtop microfuge forming two layers. For electrophoresis 
the DNA was taken from the upper layer and stored in the fridge until all time intervals 
were processed.  
 
DNA was separated and visualised on 0.8 % molecular biology grade agarose 
(Melford).  100mls 1 x TAE buffer (40 mM Tris, 20 mM glacial acetic acid (Fisher 
Scientific), 1 mM ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich), pH 8.0) 
was transferred to a 250ml conical flask 0.8g agarose was added to buffer and dissolved 
by gently heating in a microwave. After the solution had cooled but remained liquid 
5µl of Gel Red was added and swirled to mix. The agarose solution was then poured 
into gel trays, with gel combs, and allowed to solidify. Set gels were placed into a gel 
tank and immersed in 1x TAE buffer. 5µl of Lambda DNA digested with HinDIII 
ladder (Thermo-fisher Scientific) was added to first well. Samples containing DNA 
were mixed with 5x DNA loading dye (1:5) (Bioline). 5μl of each interval DNA was 
mixed with DNA loading buffer (Bioline) and loaded onto Gel Gels were run at 100V 
for up to 90 minutes. DNA bands were visualised with an ultraviolet source (G:Box, 
Syngene).  
 
The later part of the reaction was quantified by spectroscopic measurement. Separate 
reaction volumes including controls were used to for evaluation. The reaction was 
initiated as previously described and incubated for 60 mins at 37oC.  The reaction was 
halted with by the addition of 250μl of cold (4oC) 4% (v/v) perchloric acid. After 
 42 
mixing, the reaction mixture was incubated on ice for 40 minutes and then centrifuged 
at 13k rpm at 4oC in a Bench-top centrifuge (MiniSpin Eppendorf) to precipitate high 
molecular weight DNA.  250μl of the supernatant was then diluted to 1ml with Tris 
buffer and the amount of low molecular weight DNA generated measured by the 
absorbance at 260 nm using NanoDrop (ND-1000 NanoDrop) spectrophotometer. After 
appropriate cleaning and blanking of the Nano Drop 2 μL volumes of each sample were 
loaded onto the device and their values recorded (Nestle and Roberts, 1969) 
 
2.2.6. Evaluation of potential NucB toxicity to bacterial cells.  
 
To evaluate the effect of the presence of NucB on the growth rate and viability of 
bacterial cells, a series of experiments were undertaken. As previously described 
isolates were grown from glycerol stocks on to TSA plates and statically incubated over 
night at 37 0c. Representative colonies were chosen and inoculated into 5mls of sterile 
TSB and again incubated over night at 37 0C. From this overnight TSB inoculum, a 
standardised OD 600 of 0.01 was obtained by dilution with fresh TSB. 10mls of the 
subsequent standardised cultures were incubated with and without the presence of 
NucB at a concentration of 1000 ng/ml in the presence of 5mM MnS04 in falcon tubes. 
Growth of the cultures was recorded by optical density and assessment of cell numbers 
by measuring colony forming unit calculated following serial dilutions taken at hourly 
time intervals and plated onto TSA plates incubated at 370c overnight.  
 
2.2.7. Evaluation of the effect of NucB on preformed bacteria biofilms in a 96 well 
plate.  
 
To evaluate the initial effectiveness of NucB on the release of biofilm encapsulated 
bacteria, an experimental set up was adapted from Christensen et  al (Christensen et al., 
1985). Isolates from both reference strains and clinical isolates were evaluated. Samples 
maintained in a glyverol stock and stored at -800C were recovered onto TSA plate and 
incubated overnight at 37°C.  Representative colonies were chosen and inoculated into 
5mls of TSB and incubated overnight at 37°C, 200 rpm. The following morning the 
culture was diluted to produce an OD600 = 0.1, This culture was then used to create a 
biofilm formed on synthetic surface on a 96 well microtitre plate.  To form bacterial 
biofilms 180 µl were placed into each well covered and incubated statically at 37°C for 
24hours. Each experiment evaluated with each isolate in triplicate with sterile TSB 
included to act as controls. Following incubation, the liquid medium was aspirated, and 
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the plates were gently washed with sterile isotonic phosphate buffer (PBS; 10mM, pH 
7.4) to remove non-adherent cell. The residual biofilm was then exposed to either 
control or NucB. A NucB aliquot was removed from storage and brought to room 
temperature prior to utilisation. The reaction volume was pre-warmed to 370C and 
contained 50mM Tris-HCl, 5mM MnSO4.H2O (pH 8.0) plus NucB at a concentration 
of 1μg/ml which was added and mixed just prior to exposure to the biofilm. The control 
containing no NucB was included with the volume made up of sterile distilled water. 
200 µl of either NucB or control solution was pipetted into each well and incubated 
statically at 370C. After incubation all the supernatant from each well was removed and 
placed into a new sterile 96 well plate for serial dilution. The residual biofilm was 
stained with 200 µl of 0.1% crystal violet (CV) (Sigma-Aldrich, Dorset, UK) for 15 
minutes including blank wells that had solely contained sterile TSB. Excessive stain 
was removed by three serial washes with sterile distilled water. The wells were dried at 
room temperature for 30 minutes. The amount of residual biomass was quantitated by 
solubilizing the biofilms for 15 minutes with 200 µl of 33% (v/v) acetic acid as 
previously described by Merritt et al (Merritt et al., 2005). The absorbance of the CV 
solution at 595 nm were measured with a Fluostar Optima plate reader (BMG Labtech, 
Bucks, HP19 8DP, UK), using the MARS software package (BMG Labtech).  The 
removed supinated underwent serial dilution and calculation of CFU following the 
Miles and Misra method (Miles et al., 1938).  Utilising the new 96 well plate a serial 
dilution was undertaken utilising sterile PBS. In-vitro microtiter plate model using 20 
µl of suspension with 180 µl of diluent. A TSA plate was divided into 8 equal sections 
and labelled with the appropriate dilutions and dried within a microbiological safety 
cabinet. In each sector, 3 x 20 μl of the appropriate dilution is dropped onto the surface 
of the agar and the drop allowed to spread naturally. The plates are left upright in the 
microbiological safety cabinet to dry for 15 minutes before inversion and incubation at 
37 °C for 18 – 24 hours until the CFU could be counted. The following day the dilution 
with the number of colonies between 10-100 were counted. An average of the three 
samples for each isolated were obtained and the final CFU/ml calculated based on the 
dilution counted. To assist in the quantification of the  number of CFUs the open source 
Java image processing programme Image J was utilised if required (Schneider et al., 
2012). Experiments was under taken in triplicate.  
 
  
 44 
2.3. Results  
 
 
In order to establish an in vitro model of biofilm growth, 4 clinical isolates and 2 
reference strains of Staphylococcus aureus and Staphylococcus epidermidis were 
obtained. These are summarised below. 
 
 
2.3.1. Isolation of clinically relevant strains of bacteria 
 
Organism Strain Source Site 
 
Staphylococcus 
aureus 
76901 
Newcastle upon Tyne 
Hospitals NHS 
Foundation Trust 
Prosthetic joint 
infection 
518F 
Newcastle upon Tyne 
Hospitals NHS 
Foundation Trust 
Prosthetic joint 
infection 
Staphylococcus 
epidermidis 
76933 
Newcastle upon Tyne 
Hospitals NHS 
Foundation Trust 
Prosthetic joint 
infection 
096R 
Newcastle upon Tyne 
Hospitals NHS 
Foundation Trust 
Prosthetic joint 
infection 
 
 
 
 
 
 
 
 
 
 
* also known as American Type Culture Collection ATCC 9144 
** also known as American Type Culture Collection ATCC 14990 
 
The above clinical isolates strains were sourced from patients undergoing revision 
surgery for implant associated infection from regional hospitals in the North-East of the 
 
 
Table 1. Clinical isolates evaluated for their ability to form biofilm and sensitivity to NucB 
Table 2. Reference strains evaluated for their ability to form biofilm and sensitivity 
to NucB 
Organism Strain Source Site 
Staphylococcus aureus  6571* 
National Collection of 
Type Cultures  
nasal cavity 
Staphylococcus 
epidermidis 11047** 
National Collection of 
Type Cultures 
nasal cavity 
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UK. Clinical isolates were obtained from the National Culture Collection. These 
isolates were used for the subsequent use in the biofilm in-vitro model.  
 
 
2.3.2. Visualisation of biofilm formation by CLSM 
 
Having obtained the clinical isolates and reference strains the ability of these organisms 
to form a biofilm was established by CLSM microscopy. The presence of eDNA was 
evaluated with the use of YOYO-1. These results are presented in figures 6 and 7  
 
 
 
 
Figure 6. CLSM images of biofilm of a) Staphylococcus epidermidis 096R   b) 
Staphylococcus  epidermidis 76933 c) Staphylococcus  aureus 518F  d) 
Staphylococcus  aureus 76901. Established on glass cover slips stained with Nile Red 
= Membrane Dye and YOYO-1  = eDNA Dye visualised with CLSM. Scale bar = 
30µm  
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Figure 7. CLSM images of biofilm of a) Staphylococcus aureus 6571 NCTC  b) 
Staphylococcus  epidermidis 11047 NCTC established on glass cover slips stained 
with Nile Red = Membrane Dye and YOYO-1  = eDNA Dye visualised with CLSM 
Scale bar = 30µm  
 
CLSM has the ability to demonstrate the complex and variable structure of the biofilm 
matrix.   
 
 
 
 
Figure 8. CLSM image of focused view of Staphylococcus aureus biofilm established 
on glass cover slips stained with Nile Red = Membrane Dye and YOYO-1  = eDNA 
Dye visualised with CLSM. a) YOYO-1  b) Nile Red c) combined Scale bar = 5µm  
 
 
 
Figure six and seven show biofilm formation by clinical isolates and reference strains 
established on glass cover slip. All clinical isolates demonstrated the ability to form 
biofilm. The use of YOYO-1 to stain extracellular DNA confirms that all clinical 
isolates and reference strains have eDNA as part of the biofilm matrix. Figure 8 
demonstrates the immediate relationship between biofilm encapsulated bacteria and 
eDNA indicating a fundamental role for eDNA in the biofilm matrix.  
 
 
 
a b 
a b c 
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2.3.3. Effect of variation in TSB concentration on biofilm formation  
 
 
In order to establish the growth conditions which provided the most abundant and 
reproducible biofilm, a series of experiments were undertaken using increasing 
concentration of tryptic soy broth (TSB). The bacterial cell growth was quantified by 
change in absorbance for four different concentrations of growth media, these are 
summarised below.  
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Figure 9. Effect of varying concentrations of TSB media on biofilm formation of a) 
SA 79601 b) SA 518F c) SE 096R  d) SE 76933 e) SA 6571 f) SE11047 clinical 
isolates and reference strains established in 96 microtiter plates.  Measured by 
staining with crystal violet and determining the attenuance at 595 nm (A595) each 
experiment was repeated in triplicate (n=3). The graph is presented as the mean and 
standard deviation.  
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Figure nine summarises the effects of TSB concentration on the biofilm formation. In 
all cases the most abundant biofilm formation was seen in 100% TSB concentration, 
with biofilm formation falling comparatively as concentration of TSB decreased. Apart 
from SA 76901 little biofilm was formed in 10% and 20% concentrations. Biomass 
produced at all TSB concentrations showed little variation between experimental 
replicates. The 100% TSB concentration provided the most consistent biomass for all 
isolates. 
 
 
 
2.3.4. Assessment of enzyme activity  
 
In order to be used as part of a diagnostic tool, NucB should display stable and 
reproducible enzyme characteristics. To ensure consistency of experimental conditions 
a series of experiments were devised to evaluate the reproducibly and efficacy of the 
enzyme NucB at DNA digestion. To test the efficacy of the nuclease activity two 
separate experiments were undertaken to quantify the digestion the calf thymus DNA 
substrate. The early reaction was evaluated by gel electrophoresis. Figure ten 
demonstrates that after exposure of NucB to Calf thymus DNA significant digestion 
has occurred after 15 minutes when compared no enzyme control. Further time points 
of thirty and sixty minutes demonstrates further digestion. The later part of the reaction 
was evaluated using quantifiable spectroscopic analysis. Figure eleven shows the 
absorbance levels obtained from calf thymus DNA following exposure to three 
different NucB preparations following 60min exposure. NucB preparation A and B 
showed a comparable level of activity with no significant difference P = 0.942, with 
NucB preparation C demonstrating a significant decrease in active compare to 
preparation A and B (P = 0.001). To ensure that the enzyme activity did not deteriorate 
while stored over the experimental period. NucB preparation A was evaluated over a 
60-day time period figure 12 There was no significant variation in the enzyme activity 
over the 60 days.  
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M = molecular weight markers (Lambda DNA digested with HinDIII) 
Time intervals 15 mins, 30 mins,60 mins, c = no NucB, n= NucB) 
 
Figure 10. Image of gel electrophoresis from NucB digestion of DNA Result of 
digesting 125 micrograms of calf thymus DNA with 5ng NucB in Tris buffer for 15, 
30 and 60 minutes.  Samples of the digestion products were separated by agarose 
(0.8% w/v) gel electrophoresis. C = NucB control N = NucB 
 
 
 
 
 
 
 
 
 
 51 
2.3.5. Assessment of the later enzyme digestion of DNA 
 
 
 
Figure 11.  Evaluation of the activity of varying preparations of the enzyme NucB 
Results of assays with NucB from three independent preparations  ( A-C).  In each 
assay 10ng of NucB was used to digest 125 micrograms of CT DNA in Tris buffer at 
37oC for 60 minutes. repeated in triplicate (n=3) and presented as the mean and 
standard deviation 
 
 
 
Figure 12. Results of the variation in activity for NucB Preparation A overtime (days) 
In each assay 10ng of NucB was used to digest 125 micrograms of CT DNA in Tris 
buffer at 37oC for 60 minutes each analysis was repeated in triplicate (n=3)  Graph 
presented as mean and standard deviation from mean  
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2.3.6. Assessment of the presence of NucB on bacterial cell growth  
 
 
 
 
Figure 13. Effect of the presence of NucB on the growth of clinical isolates of 
Staphylococcus aureus (a + b) and Staphylococcus epidermidis (c + d) CFU/ml in 
TSB culture incubated statically at 37 0c  over time. Demonstrated by the calculation 
of CFU/ml repeated in triplicate (n=3)  and presented as the mean and standard 
deviation. 
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Figure 14 Effect of the presence of NucB on the growth of clinical isolates of 
Staphylococcus aureus (a + b) and Staphylococcus epidermidis (c + d) in TSB culture 
incubated statically at 37 0C over time. Expressed as change in optical density and 
repeated in triplicate (n=3)  and presented as the mean and standard deviation 
 
 
 
 
 
These experiments were undertaken to evaluate the potential toxicity of the nuclease 
NucB on bacterial cell growth. There was no demonstrable effect on the presence on 
NucB on Staphylococcus aureus and Staphylococcus epidermidis growth seen in figure 
thirteen and fourteen.  Both strains were able to demonstrate standard growth curves 
with the Staphylococcus aureus isolate exhibiting slightly faster growth as expected. 
Having established the efficacy of NucB, its effect on the release of preformed bacterial 
biofilms was evaluated. 
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2.3.7. Effect of NucB on release of biofilm encapsulated bacteria from clinical 
isolates 
 
 
Having isolated and evaluated clinical isolates and reference strains of Staphylococcus 
aureus and Staphylococcus epidermidis, optimised their growth conditions and 
analysed their ability to form biofilm containing eDNA. The ability of NucB to release 
biofilm encapsulated bacteria formed in microtiter plates were subsequently evaluated. 
this was quantified by CV assay and supernatant CFU/ml calculations.  
 
 
Figure 15. Effect of NucB on preformed Staphylococcus aureus and Staphylococcus 
epidermidis biofilms measured by determining the attenuance of the residual biomass 
at 595nm  repeated in triplicate (n=3) and presented as mean and standard deviation. * 
= statistical significance un-paired student t-test (P <0.05)  
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Figure 16. Effect of NucB on the preformed biofilms from clinical isolates of 
Staphylococcus aureus and Staphylococcus epidermidis (CFU/ml) repeated in 
triplicate (n=3) and presented as the mean and standard deviation. * = statistical 
significance un-paired student t-test (P <0.05) 
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2.3.8. Effect of NucB in biofilm dispersal on reference strains  
 
 
 
 
Figure 17. Effect of NucB on the preformed biofilms of Staphylococcus aureus 6571 
and Staphylococcus epidermidis 11047 reference strains measured by determining the 
attenuance of the residual biomass at 595nm repeated in triplicate (n=3)  and 
presented as mean and standard deviation * p = 0.0432 un-paired student t-test (P 
<0.05) 
 
 
 
 
 
Figure 18. Effect of NucB on preformed biofilms of isolates of Staphylococcus aureus  
6571 Staphylococcus epidermidis 11047 reference strains CFU/ml) repeated in 
triplicate (n=3) and presented as the mean and standard deviation. * = significance un-
paired student t-test (P <0.05) 
 
Figure 17 and 18 summarises these results. NucB showed a significant reduction in 
biomass by crystal violet quantification from all clinical isolates of Staphylococcus 
aureus and Staphylococcus epidermidis. The reference strain of Staphylococcus aureus 
reference strain, demonstrated a statistically significant reduction with a p 0.0432, while 
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Staphylococcus epidermidis reference strain did not reach a statistical reduction p 
0.1365.  The clinical strains demonstrated a similar reduction in biomass when 
comparing Staphylococcus aureus and Staphylococcus epidermidis. The number of 
viable cells released (measured as CFU/ml) from the biofilm by addition of NucB was 
in all cases statistically greater than the control. Again, similar numbers of viable cells 
were released from both Staphylococcus aureus and Staphylococcus epidermidis 
isolates.  
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2.4. Discussion 
 
 
2.4.1. Rationale for the choice of bacterial isolates selected for evaluation 
 
The initial aim of this chapter was to obtain and characterise clinical isolates and 
reference strains of bacteria commonly isolated from prosthetic joint infections. Six 
isolates were obtained, two clinical isolates and one reference strain for both 
Staphylococcus aureus and Staphylococcus epidermidis - table 1 and 2. The reference 
strains used were not isolated from the prosthetic joint infection but rather the nasal 
cavity. They are routinely used in in-vitro biofilm models (Liu et al., 1997, Fey and 
Olson, 2010, Jeyaseelan and Jashothan, 2012) and are well characterised having been 
used for many years. These reference strains, considered representative for their 
species, are widely available, standardised and allow comparisons between varying 
interventions. There are however, disadvantages to solely using reference strains. 
Firstly, it is recognised that reference strains originally isolated from clinical setting 
will over time become less virulent (Fux et al., 2005).  An example being the successful 
production of the BCG vaccination (Luca and Mihaescu, 2013) where successive sub 
culturing resulted in a non-pathogenic organism able to prime the immune response 
providing host immunity without active infection.  The successive sub-culturing of 
reference strains will often select for faster growing planktonic bacterial phenotype.  
For example, successive culturing of Escherichia coli in such conditions results in 
altered gene expression for the phenotype required for flagella formation. Flagella are 
not essential for rapid division but are key component of bacterial adhesion and 
subsequent virulence (Sendi et al., 2010).  Therefore, to provide a comparison for 
evaluation four clinical isolates were obtained. The clinical isolates were sourced from 
patients undergoing surgery for implant associated infection.  These isolates have 
demonstrated a known pathogenicity being able to colonise the synthetic joint in-vivo 
causing infection. Contextualising the relevance of this study, the production of eDNA 
has recently been evaluated by Zatorska et al. This work compared the production of 
eDNA from clinical isolates from prosthetic joint infection and those from healthy 
volunteers as well as reference strains (Zatorska et al., 2017). This research 
demonstrated that pathogenic isolates produced a greater quantity of eDNA in their 
biofilms compared to those isolated from health volunteers as well as the reference 
strains used. While these strains have not been previously utilised in an in-vitro biofilm 
model they have demonstrated their causality for the disease model being simulated.  
Generally bacterial biofilm studies have utilised reference strains and clinical isolates 
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when evaluating a novel antibiofilm approaches (Bjerkan et al., 2009, Francolini and 
Donelli, 2010, Drago et al., 2012). Therefore, to provide a breath of knowledge the 
effect of NucB was initially evaluated on both clinical isolates and reference strains. 
This tests the ability of enzymatic activity against the most aggressive clinical bacterial 
infections from the target environment as well as providing a comparison with a 
standardised isolate.  
 
2.4.2. Biofilm forming potential of isolates chosen for evaluation   
 
Having isolated and identified the bacterial isolates for study a series of experiments 
were undertaken to evaluate the ability of the chosen organisms to form biofilms. 
Results from figure six demonstrated that all clinical isolates possessed the ability to 
form biofilm. Several studies have established that Staphylococcus aureus and 
Staphylococcus epidermidis demonstrate the ability to readily form biofilms on 
synthetic surfaces (Thomas and Hancock, 2009, Fey and Olson, 2010). Both of the 
reference strains were also able to establish biofilms (figure 7). The ability of reference 
strains to form biofilms is more variable and it is recognised that reference isolates may 
demonstrate a lesser ability to form biofilms than their pathogenic counterparts (Fux et 
al., 2005). This is as a consequence of the sequential selection of planktonic broth 
cultures excluding bacteria, which have preferentially formed adherent biofilm. 
Subsequent analysis of the preferential planktonic bacterial sub-culture may lack the 
necessary phenotypes that enable the formation for biofilm seen in-vivo. This 
phenomenon has been identified in Pseudomonas aeruginosa when comparing clinical 
isolates to reference strains isolated from cystic fibrosis patients, where the clinical 
isolates more readily formed biofilm compared to the reference strains (Head and Yu, 
2003).  This phenomenon was however not seen from the reference strains selected for 
use within this study with both strains being able to develop a biofilm. This has been 
demonstrated by several other studies utilising reference strains in clinical biofilm 
experiments (Sendi et al., 2010, Drago et al., 2012, Zatorska et al., 2017). 
 
Having established that all isolates were able to form a biofilm on a synthetic surface 
the same technique of confocal microscopy was utilised to demonstrate the presence of 
eDNA with Y0-YO-1 cyanide dye.   From the same figures 6 and 7 all clinical isolates 
and reference strains of Staphylococcus aureus and Staphylococcus epidermidis utilised 
eDNA as part of their matrix.  This finding is consistent with previous earlier work 
confirming the presence and importance of eDNA in these bacterial biofilms (Biswas 
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et al., 2006, Thomas et al., 2009, Fey and Olson, 2010, Montanaro et al., 2011, Sadykov 
and Bayles, 2012). Utilising the ability of the confocal microscopy to evaluate hydrated 
biomass in-situ, figure 8 shows that eDNA is integral to the biofilm matrix being 
present in-between the bacterial cells allowing them to aggregate forming a complex 
community.  eDNA has been known to form an important structural and adhesion role 
in bacteria biofilms (Peterson et al., 2013), this similar close relation has been 
demonstrated by Schlafer et al utilising the another of the cyanide fluorescent  stains 
(Schlafer and Meyer, 2016).  The use of confocal imaging has confirmed the presence 
of eDNA in all bacterial biofilms - this being the necessary substrate for nuclease 
activity and indicates that NucB may be able to disrupt the biofilm matrix of these 
strains.  
 
2.4.3. Optimisation of the biofilm model and NucB toxicity  
 
The next stage in the development of this in-vitro model was to evaluate the optimal 
growth media concentration that provided the most abundant and consistent biofilm. In 
all cases the largest biomass was produced in the highest concentration of TSB (figure 
9).  This is most likely related to availability of nutrients allowing rapid bacterial 
division and subsequent biofilm formation. The ‘stringent effect’ was not evident in 
this model suggesting that the formation of biofilm can be related to a stress response 
to limited resources including nutrient deprivation (Jefferson, 2004).  Therefore, it 
could be expected that the lower nutrient levels of media could have produced greater 
amounts of biofilm. Since the formation of biofilm provides several other advantages 
including community habitation, defence and diversity, a genetically homogenous 
population when exposed to a potential colonisation surface has been shown to express 
a diverse response. This therefore allows a subset of the population to colonise the 
surface forming a more stable and protected biofilm encapsulated state, while other 
members of the population continue in the more motile planktonic form.  The 
availability of nutrients allows greater cell division allowing the community to adopt a 
diverse response optimising the organisms chance of survival.  
 
The use of confocal microscopy was able to confirm that all isolates were able to form 
biofilm. This ability has been corroborated with the crystal violet providing a 
quantitative assessment of biomass. This demonstrated no difference in the total 
biomass formed between reference strains and clinical isolates of Staphylococcus 
aureus and Staphylococcus epidermidis (figure 9) The literature has suggested that 
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clinical isolates can produce greater biofilm mass compared to reference strains 
(Sanchez et al., 2013). Once again, this is related to virulence and was not evident from 
the bacterial isolates utilised. The clinical isolates of both bacteria produced a similar 
total biomass to the reference strains in most media concentrations suggesting that 
while the reference strains may have been to subject to recurrent sub culturing they 
have maintained their ability to form comparable biofilms to the clinical strains.  As 
well as the volume of biomass produced the consistency of biofilm is important to 
provide a reproducible assay for evaluation.   The amount of biofilm produced at 
increasing media concentrations was consistent between replicates seen for all isolates. 
This was apart from SA 76901 at the 20% concentration. When comparing the 
Staphylococcus aureus and Staphylococcus epidermidis strains, both were able to 
produce equivalent biomass, even though the growth rate of Staphylococcus aureus is 
known to exceed that of Staphylococcus epidermidis (Mason, 1935).  The final biomass 
production seen is comparable at 24 hours incubation again allowing direct comparison. 
This series of experiments has demonstrated that the microtiter plate model has the 
ability to provide a stable reproducible biofilm for the evaluation of NucB.  Given that 
the largest and most consistent biofilms from all isolates of Staphylococcus aureus and 
Staphylococcus epidermidis were produced from 100% media concentration, this was 
the media used for the subsequent 96 well titre-plate model and later synthetic implant 
surface the model. 
 
Following the development of a successful biofilm model, evaluation of the NucB 
enzyme was undertaken to quantify its activity and evaluate potential bacterial toxicity.  
The series of experiments (figure 13 and 14) demonstrated that NucB is able to digest 
DNA and maintain enzyme activity over time with little variation between preparations. 
NucB has been well characterised and has been used over many years. It is known to 
be a small 12kDa enzyme (Nijland et al., 2010) which is heat stable being able to refold 
its structure after heating (Basle et al., 2018).  This stability and effectiveness of the 
enzyme demonstrates that NucB would have appropriate characteristics to utilise as a 
diagnostic agent. For evaluation preparation A was utilised to assess degradation of the 
eDNA component of the biofilm. The presence of NucB did not inhibit bacterial cell 
growth as demonstrated in figures thirteen and fourteen. This correlates with previous 
work with by Shakir et al demonstrating that the presence of a NucB is did not affect 
bacterial growth of the bacterial communities established on tracheoesophageal speech 
valves (Shakir et al., 2012) and from bacteria isolates commonly seen in chronic 
rhinosinusitis (Shields et al., 2013). Secondly the common pathogens in prosthetic joint 
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infection such as Staphylococcus aureus and Staphylococcus epidermidis are not naïve 
to nuclease exposure. Staphylococcus aureus produces two nucleases, one of which 
NUC1 is actively secreted to digest neutrophil extracellular traps (NETs). These NETs 
are secreted by host neutrophils to aid in phagocytosis (Berends et al., 2010, 
Thammavongsa et al., 2013).  Nevertheless, the presence of an exogenous nuclease 
specifically NucB, has not be evaluated on clinical isolates and reference strains of 
Staphylococcus aureus and Staphylococcus epidermidis. This therefore confirms that 
the presence of NucB did not influence the growth of bacterial isolates from prosthetic 
joint infection. This is fundamental to its potential use in diagnosis of infection via a 
culture method. 
 
2.4.4. Evaluation of the effect of NucB on biofilm disruption.  
 
Having established a reproducible model of biofilm formation and evaluated the 
activity of NucB, its effectiveness on the release of biofilm encapsulated bacteria was 
evaluated. The nuclease NucB is effective at releasing biofilm encapsulated bacteria of 
Staphylococcus aureus and Staphylococcus epidermidis (figures 16 and 18). This is key 
to the successful use of NucB as a potential agent in biofilm associated infection which 
relies on the ability of the enzyme to digest DNA and dismantle the biofilm. This 
effectiveness of NucB has been echoed in early studies in bacteria biofilms from 
isolates not related to prosthetic joint infection. Work undertaken by the Nijland et al 
team who initially isolated NucB identified the effectiveness of NucB on both Gram- 
positive and Gram-negative bacterial isolates (Nijland et al., 2010). These bacterial 
biofilms were environmental isolates, sequenced type strains and non-pathogen 
laboratory clones, as well as clinical isolates seen in chronic rhinosinusitis (Shields et 
al., 2013).  The results of this work correlate with published literature on other 
nucleases that have been utilised for biofilm including DNase.  A study by Tetz et al 
evaluated the effect of bovine DNase on biofilm matrix and a synergistic effect with 
antibiotics. This study utilised primarily reference strains including Staphylococcus 
aureus and Escherichia coli both known to cause PJI and other clinical isolates from 
patients in the Russian healthcare system. While the main focus was on a synergistic 
response to antibiotic treatment. The presence of the nuclease did demonstrate a 
significant reduction in biomass formed in 24 hours in 96 well microtiter plates from in 
both reference strains of Staphylococcus aureus and Escherichia coli (Tetz et al., 2009). 
While Tang et al adopting an alternative approach evaluated Staphylococcus aureus 
nuclease Nuc-1. Initially demonstrating a knock out to the  nuc1 gene has reduced 
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ability to form a biofilm and secondly that recombinant NUC1 protein could degrade 
the biofilm of Pseudomonas aeruginosa, Actinobacillus pleuropneumoniae, and 
Haemophilus parasuis (Tang et al., 2011).  This however, is the first time that nucleases 
have been evaluated on the bacterial biofilms of clinical isolates from prosthetic joint 
infection focusing of the release of viable organisms.  
 
Overall when comparing the CFU release to the reduction in biomass measured via the 
attenuance of crystal violet a greater effect has been demonstrated with the release of 
CFU. This is particularly evident with the reference strain of Staphylococcus 
epidermidis not reaching a statistically significant difference (figure 17). This effect 
may be related to the underlying mechanism of NucB in sporulation and its own 
endogenous role within the bacterial biofilm. Bacterial biofilms are known to be 
complex structures with relatively few bacteria compared to the total biomass the 
biofilm (Periasamy et al., 2012, Otto, 2013). The specific action of NucB on biofilm 
release could preferentially release bacteria from the biofilm seen in the significant 
difference in CFU but a lesser reduction in residual biomass demonstrated by the crystal 
violet assay. When reviewed in the larger context the response to the presence of NucB 
seen from bacterial biofilms isolated from prosthetic joint infection mimics the 
presence of endogenous nuclease release from many bacterial organisms. Since the 
CFU release is equivalent bacterial release and essential to the microbiological 
diagnosis of infection this method was taken forward for assessment on the simulated 
explant surface model.  
 
 
2.5. Conclusions  
 
This work has identified and characterised clinical isolates and reference strains of 
Staphylococcus aureus and Staphylococcus epidermidis confirming and optimising 
their biofilm formation in an in-vitro microtiter plate model. Nuclease digestion of 
eDNA by NucB has been quantified and subsequent confocal microscopy has 
confirmed the presence of eDNA in the biofilm matrix of the chosen organisms. 
Evaluation of the ability of NucB to digest eDNA within the biofilm and subsequently 
degrade the biofilm matrix was evaluated on both clinical isolates and reference strains. 
NucB was able to significantly increase the number of bacterial cells released from 
biofilms for all isolates with an average of a 3-4 fold increase in CFU/ml, as well as 
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leaving a significantly reduced biomass on the synthetic surface for the majority isolates 
of Staphylococcus aureus and Staphylococcus epidermidis.   
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3. Chapter 3. Release of biofilm encapsulated bacteria from simulated 
prosthetic implant surfaces by the nuclease NucB  
 
3.1. Introduction 
 
 
Having identified suitable clinical isolates and reference strains of Staphylococcus 
aureus and Staphylococcus epidermidis, optimised their growth conditions for biofilm 
formation and evaluated the effect of NucB on the release of biofilm encapsulated 
bacteria, the aims of this chapter were to develop an in-vivo model of prosthetic joint 
infection using simulated implant surfaces, rather than the microtiter plates used in the 
previous chapter. While the polystyrene microtiter plates used in the previous chapter 
provided a reproducible and stable surface for biofilm formation, this material is not 
routinely used in orthopaedic implants (Sonntag et al., 2012). The substrate 
composition is known to effect biofilm formation (Teughels et al., 2006, Rochford et 
al., 2012), therefore simulated implant surfaces were obtained in order to more 
accurately model PJI.  The first stage of this process was to review the materials 
commonly utilised in prosthetic joint replacement. The National Institutes of Health 
(NIH) in America estimated that around 8- 10% of people have a medical device 
implanted (Brandt, 2000), these devices are made from biomaterials.  An excepted 
definition of a biomaterial is a material that is able to  function in intimate contact with 
living tissue, with minimal adverse reaction or rejection by the body (Agrawal, 1998). 
The desirable qualities of a biomaterial depend on its use within the human body. This 
will differ significantly for example, when comparing a cardiac pacemaker to a total 
hip replacement.  Desirable characteristics of a joint replacements include; a 
biocompatible composition to avoid adverse tissue reactions, resistance to degradation, 
mechanical strength to sustain cyclic loading and high wear resistance to minimise 
debris generation (International and Davis, 2003). As well as mechanical properties the 
biomaterials have to adhere to manufacturing guidelines including the method of 
manufacture, the quality of raw materials, the consistency of material and importantly, 
regarding biofilms is the final surface finish and smoothness of the product. Materials 
currently used in joint replacement fall roughly into three groups, those of metals, 
polymers and ceramics (Navarro et al., 2008). Due to its advantageous mechanical 
properties almost all joint replacements have a metal component either as part of the 
body of the prosthesis or as a part of the articulating surface. Stainless steel was one of 
the first metals used in the manufacture of total joint replacements (Charnley, 1961) 
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and is still currently in use. There are several formulations available, however the most 
abundantly used is austenitic stainless steel 316L (Cahoon and Paxton, 1970). Stainless 
steel is a cheap material, with a long history of use in joint replacement. However, 
stainless steel has reduced wear characteristics when compared with other tougher 
alloys such as cobalt- chrome (Co-Cr). Cobalt-chrome alloys such as Co-Cr-Mo ASTM 
75 have been used in total hip replacements since the mid 1970’s (McKee and Watson-
Farrar, 1966). Co-Cr alloys have greater corrosion resistance compared to stainless steel 
with greater mechanical properties including a high elastic modulus which is greater 
than bone (Marti, 2000). These properties are useful when constructing joint 
replacements.  A side effect of the mechanical strength is unwanted stress shielding of 
the adjacent bone stock causing reabsorption of bone around the implant over time 
(Bauer and Schils, 1999).  Titanium alloys first used in aeronautics have demonstrated 
a lower elastic modulus and the potential for bone ingrowth known as osseointegration  
(Escalas et al., 1976). This allows direct integration of the bone to the joint without the 
need of cement to fix the prosthesis. Titanium is now frequently used in the tibial base 
plate of total knee replacements since its elastic modulus is closer to that of bone unlike 
some of the stiffer metals alloys used for the joint surface itself (Long and Rack, 1998).   
 
Common polymers used in orthopaedics implant surgery include polymethyl-
methacrylate (PMMA) bone cement and polyethylene (PE) (Kurtz et al., 1999). Of 
these, polyethylene is commonly used as an implant surface in total hip and knee 
replacements. It is employed to either form the lining of the acetabular component or 
as the insert for the tibial component. High molecular weight polyethylene (HWPE) is 
most often used and again has a long history of use within orthopaedic implants. This 
is related to its low friction, abrasion resistance and high impact compression strength 
(Atienza and Maloney, 2008). However, wear and resultant debris production remain 
the main limitation of use (Massin and Achour, 2016). 
 
Ceramics are also frequently used in joint replacement, their development was driven 
due to the potential wear characteristics of HWPE. Ceramics when used as part of the 
acetabular cup of total hip replacements demonstrate improved wear characteristics 
while maintaining the low friction properties required (Hench and Wilson, 1993) 
however, the ceramic was brittle and early designs suffered from fractures 
(Hamadouche and Sedel, 2000). Later developments of more resilient ceramic bearing 
surfaces have been utilised more recently. This suggests a growing confidence in the 
material especially with its use in high demand for the younger patient population, 
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where longevity of the implant is fundamental (D'Antonio and Sutton, 2009, Atrey et 
al., 2017).  Part of the initial work of this chapter was therefore to identify and recruit 
a range of surfaces constructed from materials commonly used in prosthetic joint 
replacement.  
 
Whilst mechanical properties primarily influence the choice of material for prosthetic 
joint replacement, in recent years there has been increasing recognition of the 
importance of biofilm infection. This has shifted the focus of material choice to 
potential anti biofilm properties of the implant materials.  Factors influencing bacterial 
adherence to a biomaterial surface include chemical composition of the material, 
surface charge, hydrophobicity and surface roughness (Katsikogianni and Missirlis, 
2004).  Surface roughness is a two-dimensional parameter that is specific to each 
material. It can be evaluated in several ways; (Poon and Bhushan, 1995) with the most 
frequent use of average roughness (Ra) and root mean square roughness (Rq). 
Generally, the smoother the surface the more resistant to bacterial adhesion 
(Scheuerman et al., 1998, Teughels et al., 2006). This is primarily related to roughness 
on a nanoscale where the rougher surface can provide a greater number of contact points 
allowing bacterial adhesion (Truong et al., 2010).  Surface roughness can vary between 
replicates of each material, the surfaces once obtained were optimised for use in a 
biofilm model primarily in terms of their surface roughness. 
 
Having obtained, characterised and optimised the chosen surfaces each were evaluated 
in its ability to host a biofilm from the clinical isolates of Staphylococcus aureus and 
Staphylococcus epidermidis utilised in chapter three. These surfaces were then utilised 
to evaluate both the efficacy of the nuclease NucB as well as sonication to offer a 
comparison to NucB.   Sonication is the process of exposing the biofilm which is 
formed on the synthetic surface to ultrasonic energy. This creates pressure changes at 
the interface dislodging the bacteria allowing them to be isolated and identified 
(Trampuz et al., 2007). As noted above sonication has proved effective in assisting with 
the diagnosis of biofilm associated prosthetic joint infection. However, it has a number 
of limitations which means its use has not been widely adopted. Nevertheless, it is the 
most established technique to assist in the release of biofilm encapsulated bacteria and 
therefore would provide a valid comparison to the effectiveness of NucB.  
 
Therefore, the aim of chapter three is to more closely simulate an infected prosthetic 
implant surface model with the use of biomaterials commonly utilised in total joint 
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replacement. In order to more closely simulate the PJI infection model the clinical 
isolates were utilised to evaluate the use of NucB in releasing biofilm encapsulated 
bacteria to assist in the diagnosis of infection with comparisons to the more established 
technique of sonication.  
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3.2. Materials and Methods 
 
3.2.1. Sourcing of and preparation of preparation of simulated implant surfaces 
 
Simulated implant surfaces were sourced from companies supplying the commercial 
manufacturers of prosthetic joint replacements. The Titanium and Cobalt-Chrome were 
provided in rod form and were cut and polished into discs either within Newcastle 
University (School of Mechanical Engineering) or at a specialist polishing company 
(Tecomet, Inc. Sheffield UK). The polyethylene pre-cut rough discs were processed 
within Newcastle University where polishing was undertaken progressively using 
silicon carbide fine grit discs on a rotary pregrinder (metasev UK) with water cooling. 
Following polishing, measurement of their surface topography and size were recorded. 
The surface roughness of all discs was evaluated using a calibrated stylus contact 
optical surface profiler ( Alpha-Step D 500 KLA Tencour USA) at room temperature 
and mean roughness (Ra) recorded (Wennerberg and Albrektsson, 2000). Disc height 
and circumference measurements were obtained for each disc using a micrometer.  
 
3.2.2. Optimisation of methods used to quantify release of biofilm encapsulated cells 
from simulated implant surfaces 
 
To evaluate the effectiveness of NucB and sonication to release biofilm encapsulated 
bacteria from a simulated implant surface the previous model was adapted from the 96 
well plate. Adaptation of the method required optimisation of a washing stage following 
inoculation and culture to remove the non-adherent bacterial cells. This then provides 
a substrate on which to evaluate the action of NucB and sonication. To evaluate the 
number of washing steps required the following experiments were undertaken.  As 
previously described, isolates were maintained in a glycerol stock and stored at -800C 
before being recovered onto a TSA plate and incubated overnight at 37°C.   
Representative colonies were chosen and inoculated into 5mls of TSB and incubated 
overnight at 37°C, 200 rpm. The following morning the culture was diluted to produce 
an OD600 = 0.1. This culture was then used to create a biofilm formed on the simulated 
implant surfaces. 
 
The simulated implant surfaces Cobalt-Chrome, Titanium and Polyethylene discs were 
washed in 1% Virkon followed by 70% ethanol and then rinsed with sterile distilled 
water.  The discs were autoclaved in a sealable container, heat dried and then allowed 
to return to room temperature. Standard checks were made to ensure the effectiveness 
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of the sterilisation process.  Using sterilised forceps, discs were transferred to a separate 
sterile 50ml Falcon tubes (Thermo Fisher Scientific).  5mls of the inoculum was then 
added to each tube and incubated statically at 37°C for 24 hours.   To ensure the sterility 
of the discs a separate disc was incubated with sterile media and checked to ensure no 
growth at the 24 hours. If contamination had occurred the experiment was abandoned.  
To establish the number of washing steps required to remove non-adherent bacteria, ten 
washing baths of 15mls sterile PBS were created for each disc. Individually each disc 
was then dipped into the subsequent sequential baths, from each of the 10 baths.  A 
sample from each of the sequential baths underwent serial dilution and calculated of 
CFU following the Miles and Misra method (Miles et al., 1938) utilising a 96 well plate 
as previously described. Following serial dilution, the samples were then plated on TSB 
plates again in a similar fashion as previously utilised. The plates were then incubated 
overnight at 37 °C for 18 – 24 hours and then CFU counted allowing an extrapolation 
to quantify the number of bacteria removed from the disc with each serial washing step. 
To ensure that the residual discs had viable biofilm encapsulated bacteria, one of discs 
from each of the material was further inoculated into sterile TSB and cultured statically 
for 24 hours at 37 °C. Following this, the OD was measured with comparisons made to 
sterile TSB which was incubated over the same time frame. To further confirm the 
amount of biomass on the inoculated discs crystal violet assay was undertaken on the 
remaining discs and with comparisons made to the control non-inoculated discs. To 
achieve this following the washing step the discs were allowed to dry and then 
transferred to a sterile polystyrene 6-multiwell plate and stained with 5ml of 0.1% 
crystal violet (CV) for 20 minutes. After washing with sterile water, the discs were 
transferred to sterile polystyrene 6-multiwell plate and the crystal violet dye was 
solubilized in 5 ml of 33% acetic acid for 30 minutes. 200μl of the solution of each well 
were transferred to a 96 well microtiter plate and the CV absorbance was recorded at 
595nm as previously described. Each of the discs were evaluated separately and 
experiments were repeated in triplicate.  
 
 
 
3.2.3. Evaluation of sonication as a method for the release of biofilm encapsulated 
bacteria 
 
To evaluate the sonication energy produced from the sonication bath (Engisonic 
EngisLtd, Kent, UK), a calibrated hydrophone visualised on a digital storage 
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oscilloscope (tektronix 2024C North America) within Newcastle University  (School 
of Electrical and Electronic Engineering) was utilised. The sonication bath was filled 
with water at room temperature and hydrophone submerged. The energy produced was 
recorded in terms of frequency and intensity. (Trampuz et al., 2007)  
 
3.2.4. Evaluation of the effect of NucB on bacterial biofilms established on 
simulated implant surfaces compared to sonication  
 
This experimental model was adapted from previous work evaluating the disruption of 
biofilms established of disc surfaces (Drago et al., 2012).  Each simulated surface was 
evaluated in individual experiments using each of the chosen bacterial isolates. Three 
discs were used for each treatment arm those being NucB, sonication, NucB control 
and where enough discs were available a combination of NucB and Sonication. Blank 
discs were also used to ensure no contamination throughout the experimental process.  
 
 
 
 
Figure 19.  Pictorial representation of the experimental process showing initial 
inoculation washing and subsequent intervention.  
 
Representative colonies were chosen and inoculated into 5mls of sterile TSB and again 
incubated over night at 37 0c. Using a spectrophotometer the absorbance at 600 nm each 
media concentration was then inoculated with the re-suspended culture to create an 
optical density of 0.01. Having standardised the inoculum 10-13 sterilised discs were 
transferred into eight sterile 50ml falcon tubes. 5mls of inoculum was added to nine of 
the tubes and one with sterile TBS used to reconstitute the inoculum to ensure the 
sterility of the discs and media. These were then incubated over night at 37 0C. The 
following morning checks were made to ensure that the control media remained clear, 
if contamination had occurred the experiment was abandoned. Following this the 
residual cultured media was removed and individual discs were immersed sequential 
six times to remove the non-adherent bacteria cells and then left to dry in a sterile 
container. Depending on requirements 9-12 discs were used and divided into three 
Inoculation washing Treatment Culture	sterilisation
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treatment groups for further evaluation, occasionally one of the discs was dropped and 
therefore discarded with the spare disc substituted.  
 
The reaction mixture for the NucB and NucB control were constituted in a single 50ml 
falcon before being divided between the discs for treatment. Pre-aliquoted 150 µl stock 
solutions of 100 µl/ml NucB enzyme were removed from -800c storage and allowed to 
thaw prior to use. The following reaction mixture was then created vortex and then 
brought to room temperature. 0.75 mL tris buffer pH8.0, 6.6 mL of MnSO4  and 7.5 mL 
Sterile distilled water, creating a final volume of 15ml The NucB solution 150 µL of 
NucB (100 µl/ml) was then added before mixing again and then divided into 5 ml 
aliquots before exposing to the discs assigned for NucB treatment. The solution for 
NucB control was constituted in the same replacing the NucB volume with sterile 
distilled water. Both the NucB and NucB controls samples were then transferred to tilt 
table at 10 revolutions per minute (Heidolph polymax 1040 Heidolph UK – Radleys 
Shire Hill Saffron Walden Essex, CB11 3AZ) at room temperature for one hour. The 
sonication method was adapted from Trampuz et al (Trampuz et al., 2007). Discs with 
established biofilm were transferred to sterile containers with 5ml PBS solution. The 
falcon tubes were initially vortexed for 30 seconds using a Vortex-Genie 2 (Scientific 
Industries) before being transferred to the sonication bath (engisonic EngisLtd, Kent, 
UK) for 5 minutes, followed by subsequent vortexing for 30 seconds.  To evaluate a 
synergistic effect of the combination of NucB and Sonication on the recovery of 
bacteria Polyethylene and Co-Cr discs were exposed initially to sonication and then 
subsequent NucB Treatment following the above methods.  
 
Having undergone either treatment by sonication, NucB, NucB control or combined 
treatment the 200 µl from each sample was then removed and transferred to a sterile 96 
well plate where a serial dilution was undertaken before pipetting onto TSA plates as 
previously described. These plates were then incubated over night before CFU units 
were recorded. Knowing the surface area of the discs the CFU/mm2 for each of the 
discs were recorded for each of the bacterial isolates tested. Results were analysed using 
un paired student t-tests and presented using Prism 7.0 (Graph-pad Software 
incorporated USA). Statistical significance was considered at a value of p ≤ 0.05. 
 
 
 
 73 
3.3. Results  
 
In order to create a simulated prosthetic joint infection model discs of material 
commonly used in joint replacements were first recruited. These are summarised in the 
table below. 
 
3.3.1. Simulated prosthetic implant surfaces 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table three summarises the materials that were obtained to stimulate a prosthetic joint 
replacement. All of the surfaces were obtained from companies that supply the 
manufactures of prosthetic implants therefore, meeting the requirements for use as 
medical devices.  
 
 
 
 
 
 
 
3.3.2. Preparation of simulated implant surfaces  
 
In order to ensure there was no variation between the size and surface roughness of the 
discs obtained following optimisation the results are summarised in the table below.  
Table 3. Summary of simulated prosthetic implant surfaces used for evaluation of biofilm 
dispersal 
Titanium 
 
Titanium 6AL4V ELI ASTM 
F136 Grade 23 
Source: Ti industries Birmingham 
UK 
Cobalt-Chrome 
Cobalt-chrome-Mo Alloy ASTM 
75 
Source: Acnis international 
Villeurbanne France 
Polyethylene 
High molecular weight 
polyethylene (HMPE) 
Source: Biosurface Technologies 
Corporation Montana USA 
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Table 4. Summary of size and surface area of simulated implant surfaces 
 
  Size 
Surface Average depth mm Average radius mm Surface area mm2 
Titanium 3.95 8.97 727.85  +/-  1.88 
Cobalt-Chrome 5.08 8.99 794.65  +/-  3.18 
Polyethylene 5.81 10.6 1092.60  +/-  1.38 
 
Table 5. Summary of the surface roughness of simulated implant discs 
 
  Surface roughness 
Surface Ra Rq 
Titanium 0.551  +/-  0.172 0.698  +/- 0.059 
Cobalt-Chrome 0.196  +/- 0.017 0.255  +/- 0.028 
Polyethylene 0.669  +/-  0.100 0.789  +/- 0.059 
 
Table 4 and 5 summarise the surface characteristics of the simulated implant surfaces 
used to evaluate biofilm disruption, including standard deviations seen between the 3 
discs. Ra = Average roughness for a given sample length. Rq = Root mean square 
roughness for given sample length. The discs available were evaluated to ensure 
conformity allowing direct comparison between the interventions. The variation seen 
between discs was minimal in terms of their surface topography and size. The Ra and 
Rq values identified that the Co-Cr surface was the smoothest surface followed by 
Titanium and Polyethylene. 
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3.3.3. Optimisation of biofilm formation on simulated implant surfaces. 
 
 
 
Figure 20. Demonstration of the effect of washing on the number of non-adherent 
bacteria removed from the simulated implant surface evaluated by CFU/mm2. 
Repeated in triplicate (n=3) and presented as the mean and standard deviation 
 
 
 
As expected high numbers of CFU were initially washed from the discs in the early 
washes 1 and 2 from all of the surfaces utilised. Having completed the 6th wash there 
was no significant further reduction in the CFU released for all of the surfaces. Six 
washes were therefore chosen for the simulated prosthetic implant surface model. 
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Figure 21.  Biomass remaining following washing from each of the isolates utilised 
on simulated implant surfaces Absorbance/mm2 Repeated in triplicate (n=3)  and 
presented as the mean and standard deviation 
 
 
 
Absorbance levels demonstrate that the polyethylene surface had the highest biomass 
following the washing stages with cobalt chrome and titanium demonstrating similar 
readings. Over all Staphylococcus aureus and Staphylococcus epidermidis biomass was 
comparable over all of the surfaces utilised.  
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3.3.4. Calibration of sonication technique for simulated implant surfaces 
 
Energy calculations for the sonication machine were undertaken using a calibrated 
hydrophone at the School of Electrical and Electronic Engineering at Newcastle 
University. A frequency of 40 kHz and intensity of intensity 62 w/m2 was demonstrated 
from the sonication device utilised during the experimental process.  
 
 
 
3.3.5.  Effect of NucB on bacterial biofilms established on simulated implant 
surfaces compared to sonication 
 
 
 
Figure 22. Effect of the presence of NucB on the release of Staphylococcus 
epidermidis 76933 from biofilms grown on simulated implant surfaces compared to 
sonication. Repeated in triplicate (n=3)  and presented as the mean and standard 
deviation 
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Figure 23. Effect of the presence of NucB in release of Staphylococcus epidermidis 
096R on biofilm encapsulated bacteria on simulated implant surfaces compared to 
sonication Repeated in triplicate (n=3) and presented as the mean and standard 
deviation 
 
 
Figure 22 and 23 demonstrate the effect of the presence of NucB in release of SE 096R 
and SE 76933 (clinical isolates) biofilm encapsulated bacteria on simulated implant 
surfaces compared to sonication. * indicates a significant difference (P < 0.05) un-
paired t-test ** indicates no significant difference (P > 0.05) un-paired t-test Graph 
plotted with mean and standard deviation 
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Figure 24. effect of the presence of NucB in release of Staphylococcus aureus 518F 
biofilm encapsulated bacteria on simulated implant surfaces compared to sonication * 
indicates a significant difference (P < 0.05) un-paired t-test  ** indicates no 
significant difference (P > 0.05) un-paired t-test. Repeated in triplicate (n=3), graph 
plotted with mean and standard deviation 
 
Figure 25. Effect of the presence of NucB in release of Staphylococcus aureus 76901 
biofilm encapsulated bacteria on simulated implant surfaces compared to sonication. * 
indicates a significant difference (P < 0.05) un-paired t-test  ** indicates no 
significant difference (P > 0.05) un-paired t-test.  Repeated in triplicate (n=3) , graph 
plotted with mean and standard. D No significant difference on un-paired t-test 
between NucB and Sonication  
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The above graphs summarise the effect of NucB on the release of biofilm encapsulated 
bacteria from simulated implant surfaces compared to a NucB control and sonication. 
NucB was significantly more effective than NucB control in all isolates and on all 
surfaces evaluated. NucB was comparable to sonication with no significant differences 
for both isolates of Staphylococcus epidermidis and Staphylococcus aureus isolate SA 
518F this was evident on all three surfaces. When evaluating SA 76901 on polyethylene 
surface sonication demonstrated a significant difference compared to NucB treatment 
(P = 0.014). The other surfaces of Co-Cr and Titanium evaluated with the 
Staphylococcus aureus isolate SA 76901 demonstrated comparable results with NucB 
and sonication treatment.  
 
 
3.3.6. Effect of combination NucB and sonication on release of biofilm encapsulated 
bacteria from prosthetic implant surfaces.  
 
 
 
Figure 26. Effect of the combination of NucB and sonication on Staphylococcus 
epidermidis biofilms formed on polyethylene surfaces ** indicates a significant 
difference (P < 0.05) un-paired t-test  * indicates no significant difference (P > 0.05) 
un-paired t-test. Repeated in triplicate (n=3), graph plotted with mean and standard 
deviation 
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Figure 27. Effect of the combination of NucB and sonication on  Staphylococcus 
epidermidis biofilms formed on cobalt-chrome surfaces ** indicates a significant 
difference (P < 0.05) un-paired t-test  * indicates no significant difference (P > 0.05) 
un-paired t-test. Repeated in triplicate, graph plotted with mean and standard 
deviation 
 
 
 
 
 
Figure 28.  Effect of the combination NucB and sonication on Staphylococcus aureus 
biofilms formed on polyethylene surfaces ** indicates a significant difference (P < 
0.05) un-paired t-test * indicates no significant difference (P > 0.05) un-paired t-test. 
Repeated in triplicate (n=), graph plotted with mean and standard deviation 
 
SE
 06
93
3
Nu
cB
 
SE
 06
93
3
So
nic
ati
on
 
SE
 06
93
3
Co
mb
ine
d S
on
ica
tio
n 
an
d N
uc
B S
E 0
96
R
Nu
cB
 
SE
 09
6R
So
nic
ati
on
 C
o-C
r
SE
 09
6R
 C
om
bin
ed
 So
nic
ati
on
 
an
d N
uc
B 
0
20000
40000
60000
80000
C
FU
/m
m
2
Combined Sonication and NucB on Staph epi Isolates Using Co-Cr
*
* *
*
SA
 76
90
1
 N
uc
B
SA
 76
90
1 
So
nic
ati
on
SA
 76
90
1
 C
om
bin
ed
 So
nic
ati
on
 
an
d N
uc
B
SA
 51
8F
 N
uc
B
SA
 51
8F
 
So
nic
ati
on
SA
 51
8F
 C
om
bin
ed
 So
nic
ati
on
 
an
d N
uc
B
0
20000
40000
60000
80000
C
FU
/m
m
2
Combined Sonication and NucB on Staph aureus Isolates  using Poly
**
*
*
*
 82 
 
Figure 29. Effect of the combination NucB and sonication on Staphylococcus aureus 
biofilms formed on cobalt-chrome surfaces ** indicates a significant difference (P < 
0.05) un-paired t-test * indicates no significant difference (P > 0.05) un-paired t-test. 
Repeated in triplicate (n=3) , graph plotted with mean and standard deviation 
 
 
 
 
Combining the NucB and sonication treatment did not significantly increase the yield 
from the isolates of both Staphylococcus epidermidis isolates and Staphylococcus 
aureus isolate SA 518F. There were no significant differences seen between the release 
of colony forming units when comparing combined NucB and sonication treatment 
with either standalone treatment with NucB or sonication. Staphylococcus aureus 
isolate SA76901 demonstrated a significant increase in the CFU release when 
comparing NucB treatment to combined treatment on the surfaces of polyethylene (P = 
0.0352) and Co-Cr (P = 0.0027). No significant differences were seen when comparing 
sonication and a combination of NucB and sonication for SA 76901 on these surfaces.  
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3.4. Discussion 
 
 
3.4.1. The biofilm model chosen for initial evaluation of the action of NucB 
 
In vitro biofilm assays are a crucial first step in the assessment of the therapeutic 
effectiveness of novel anti- biofilm agents such as the nuclease NucB. The disc model 
utilised aimed to simulate more accurately a prosthetic joint surface.  Similar models 
have been used to evaluate and compare several anti-biofilm agents in prosthetic joint 
infection  (Bjerkan et al., 2009, Drago et al., 2013, Chen et al., 2016, Prieto-Borja et 
al., 2017) as well as the evaluation of several other biofilm systems including oral dental 
health and food production (Kadkhoda et al., 2016, Madeira et al., 2016). However, this 
model has not previously been used for the evaluation using nuclease activity of biofilm 
disruption. The disc model chosen ensured the evaluation of the unique prosthetic 
implant material utilised in clinical practice was reproducible, consistent as well as 
allowing the comparison with the sonication technique.  Currently no in vitro model 
exists that can simulate the biomechanical environment within a prosthetic joint 
replacement (Drago et al., 2013). Other models do exist to evaluate the biofilm 
formation. These however would not have allowed the elevation of the specific implant 
surface used in hip and knee arthroplasty nor would they have more closely simulated 
the replaced implant (Coenye and Nelis, 2010, Coenye and Bjarnsholt, 2016).  
 
The disc biofilm model utilised three surfaces. Titanium, Cobalt-Chrome and 
Polyethylene. These surfaces are commonly used in prosthetic joint replacement as 
previously discussed (Ribeiro et al., 2012).  Stainless steel while still routinely used 
was difficult to source for evaluation. Several steel formulations were available 
however, 316L used for prosthetic joint replacement was only available in industrial 
quantities and was therefore not evaluated in this study. All of the other materials 
sourced were from suppliers that supplied the implant manufactures. Evaluation of the 
surfaces (table 4 and 5) demonstrated high concordance and tolerance in terms of 
variation of disc size and surface topography. Several techniques are available for the 
evaluation of surface topography the Ra and Rq values are accurate and frequently used 
to evaluate surface characteristics in orthopaedic implant surfaces (Munir et al., 2015). 
The surface roughness measured as Ra and Rq values achieved were comparable to the 
surface roughness of explanted joints and other studies utilising disc models for PJI 
(Bjerkan et al., 2009, Sorrentino et al., 2018).  Surface roughness is one of the key 
components of bacterial biofilm initial adhesion and subsequent biofilm attachment 
 84 
(Bazaka et al., 2011, Rochford et al., 2012). One advantage of this disc model was the 
high fidelity of the surface topography and disc material compared to actual joint 
prosthesis which other studies have not achieved (Drago et al., 2012). These subtle but 
important changes in material use as discussed can have a dramatic influence on the 
biofilm characteristics and therefore the subsequent interpretation results.  
 
3.4.2. Optimisation of the disc model for biofilm evaluation  
 
Having sourced the disc surfaces, optimisation of the biofilm disc model was 
undertaken. Of particular interest was the number of washing steps required to remove 
non-biofilm encapsulated bacteria. A review of several studies demonstrated variation 
in the numbers of washing steps using a comparable model. Drago et al using similar 
clinical isolates advocated three washes (Drago et al., 2012) while Bjerkan et al utilised 
six (Bjerkan et al., 2009). Optimisation of the washing steps (summarised in figure 20) 
demonstrated that six washes removed non-adherent bacteria. Several published studies 
using a disc model did not optimise the number of washing steps. Failure to remove the 
non-biofilm associated bacteria will lead to a subsequent over estimation of the 
effectiveness on any intervention when evaluating the retrieval of colony forming units. 
Examination of the subsequent biomass formation following the washing steps 
(summarised in figure 21) demonstrated that per mm2 the polyethylene surface was the 
most heavily colonised in all isolates. Current literature would support this finding; the 
polyethylene surface was the roughest surface and surface roughness has previously 
been described as one of the strongest factors for bacterial biomass formation.  (Ribeiro 
et al., 2012). The hydrophilicity of polyethylene is important in the initial bacterial 
attraction to the implant surface and is another factor in increasing bacterial biofilm 
formation for this surface (Banche et al., 2014). 
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3.4.3. Sonication technique adopted for evaluation of biofilm disruption  
 
Significant variation exists in the sonication techniques utilised within the published 
literature (Monsen et al., 2009). Several variables exist including the sonication energy 
that the implant or discs are exposed to. For this study, the original technique reported 
by Trampuz et al was adopted (Trampuz et al., 2007). A review by Monsen et al 
demonstrated that the optimal sonication energy to maintain bacterial viability was 40 
kHz (Monsen et al., 2009). Other studies have adopted a lower sonication energy of 30 
kHz (Drago et al., 2012, Bjerkan et al., 2009). Sonication itself is bactericidal and this 
effect has historically been used in the control of bacterial biofilms in manufacturing 
and food industry (Burleson et al., 1975). It is also utilised in the sterilisation of medical 
instruments (Jatzwauk et al., 2001). Monsen et al demonstrated that ultrasonic energy 
had a potential inhibitory effect on bacteria. Erriu et al demonstrated that Gram-
negative bacteria such as Escherichia coli which are known to cause prosthetic joint 
infection, are particularly sensitive with short exposures proving bactericidal (Erriu et 
al., 2014). 
 
3.4.4. Effect of NucB on bacterial cell release and comparison to sonication  
 
Having established a reliable model, the main focus of this chapter was to evaluate the 
effectiveness of NucB on the release of encapsulated bacteria. Overall, (summarised in 
figures 22 – 25) NucB demonstrated a statistically greater release of bacteria when 
compared to a non-NucB control. The non-NucB control group did demonstrate a 
detectable release of CFU from the discs but to a lesser extent. This may be related to 
the release of residual bacteria that were not biofilm encapsulated and were not 
removed during the washing step or the mechanical effect of the tilt table that the NucB 
and NucB control experiments were exposure to could be responsible for the back 
ground CFU released. Nevertheless, the natural cycle of the biofilm is of dispersal and 
flocculation. As previously mentioned the biofilm community is known to degrade its 
own biofilm to allow colonisation of new environments (Stoodley et al., 2002) This 
forms and essential part of the bacterial biofilm community (Costerton et al., 1999, 
Hall-Stoodley et al., 2004). Several studies have used a comparable model but have not 
included a control group for the intervention they are evaluating. Instead their 
intervention is compared to another technique for removal of biofilm such as scraping, 
sonication, DTT or NAC (Bjerkan et al., 2009, Drago et al., 2012). Bjerkan and Drago 
et al both demonstrated that sonication was effective at removal of biofilm encapsulated 
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bacteria from discs of a simulated implant surface. Differences in methodology prevent 
direct comparison, however the effectiveness of sonication was again demonstrated in 
this study.  
 
Sonication was more effective in the release of biofilm encapsulated bacteria of the 
clinical isolate of Staphylococcus aureus SA 76901 on the surface of polyethylene. On 
the remaining surfaces of titanium and Co-Cr NucB and sonication demonstrated no 
significant difference for the same isolate. This would suggest that the SA 76901 isolate 
forming of polyethylene discs were more resistant to the effect of the nuclease. This 
may relate to the composition of the biofilm forming on polyethylene and its 
dependence on eDNA. The composition of the biofilm matrix is known to vary relating 
to several factors including the host surface (Costerton et al., 1999, Biswas et al., 2006, 
Arciola et al., 2012). This is related to the expression of adhesion molecules which are 
up or down regulated by the same isolate depending on environmental pressures. The 
nuclease NucB however, was for this isolate, on all surfaces more effective than the 
NucB control. The combination of sonication and NucB as expected therefore showed 
a slightly greater effect on the isolate Staphylococcus aureus SA 76901 (figure 28) on 
polyethylene but also for the same isolate on Co-Cr. This would suggest that overall 
biofilms of this isolate may be more resistant to nuclease mediated degradation, while 
still producing a significantly greater response overall compare to the NucB control.  
Sonication seemed to demonstrate less variation on the isolates investigated. This could 
be expected due to the mechanical nature of its action. However, as discussed, this 
mechanical action may be bactericidal reducing the number of CFU identified. 
Sonication could therefore demonstrate a degree of variability in viable CFU especially 
in gram negative bacteria (Erriu et al., 2014). The combination of NucB and sonication 
therefore may have resulted in a reduction of CFU recovered since the sonication 
energy may have killed bacteria already released from the biofilm by the action of the 
nuclease. However, this effect was not demonstrated.  
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3.5. Conclusions 
 
This chapter has developed from the initial evaluation of NucB in chapter two. Having 
developed and evaluated the surface model of PJI, NucB was able to demonstrate a 
statistically greater number of CFU released when compared to controls. Overall, NucB 
was able to release comparable CFU to sonication from the majority of clinical surfaces 
evaluated. The combination of sonication and NucB improved the release of one 
isolated of Staphylococcus aureus from the surfaces evaluated when compared to NucB 
treatment alone.  The results from chapters two and three have demonstrated for the 
first time the effectiveness of the nuclease NucB on the release of biofilm encapsulated 
bacteria from isolates commonly seen PJI joint infection. The demonstration that 
nuclease remains effective at bacterial release when biofilms have been established on 
the more complex surfaces of Chrome, Titanium and Polyethylene provide confidence 
in the further development of the use of NucB in the diagnosis of infection in PJI. This 
potential will be further evaluated in Chapter four.  
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4. Chapter 4.   Release of biofilm encapsulated bacteria from explanted joints: a 
comparison of NucB and sonication 
 
4.1 Introduction 
 
Having established an in-vitro model of an infected prosthesis using simulated implant 
surfaces, a process was developed for evaluation of NucB on explanted joint prostheses. 
Chapters 2 and 3 evaluated the effect of NucB on the clinical isolates and reference 
strains for the most common causative organisms in PJI. Furthermore, the use of the 
simulated joint surfaces allowed the comparison of the NucB technique to sonication 
as well as creating a higher fidelity model of PJI. Within these experimental setup NucB 
was able to demonstrate its effectiveness. The subsequent challenge therefore is the 
evaluation of NucB on the actual explanted joint prosthesis from patients undergoing 
revision surgery.  This will exposure the NucB technique to much wider selection of 
causative organisms and the actual clinical entity for which it may have a potential role 
in the diagnosis of infection.  An initial review and assessment was undertaken into the 
standard processing of microbiology samples for PJI within the NHS and in particularly 
Northumbria Healthcare NHS Foundation Trust. Prospective ethical approval was 
obtained to recruit a cohort of patients undergoing revision surgery for joint arthroplasty 
of the hip and knee. The implants recovered were assigned to either NucB, non-NucB 
control or sonication treatments and the CFU from each technique recorded. Key to the 
potential use of NucB to assist in the diagnosis of PJI within the NHS is the ability of 
the NucB treated samples to be incorporated into automated microbiological culturing 
system Bactec ® system. The compatibility of NucB and the Bactec ® system was 
evaluated and an initial review into how NucB maybe combined with the current 
microbiological  samples taken to evaluate PJI. 
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4.2 Material and Methods 
 
4.2.1 Ethical approval for use of explanted joint prostheses 
 
Ethical approval was granted for a prospective cohort study via a substantial 
amendment evaluating a potential biomarker for prosthetic joint infection (IRAS 
project ID: 133171) This was granted by NRES Committee North East - Tyne & Wear 
South REC reference: 13/NE/0270. Ethical approval was obtained for a prospective 
study to investigate the potential of a novel diagnostic technique on explanted joints 
recovered at the time of revision surgery Recruitment commenced on the 7th June 2015 
with the study closing on the 30th June 2016. 
 
4.2.1 Evaluation of current standard practice for the identification of prosthetic 
joint  infection within Northumbria Healthcare NHS Foundation Trust. 
 
Prior to planned revision surgery for joint replacement a standardised assessment of the 
patient was undertaken. This practice is based upon guidance provided by the UK 
Standards for Microbiology Investigations (SMIs) (SMI-B44, 2017). Patients 
underwent clinical evaluation in terms of history and clinical examination. Plain film 
radiographs and baseline blood tests including inflammatory markers were obtained. 
Routinely all patients were discussed at a multidisciplinary meeting involving 
orthopaedic surgeons, infectious disease doctors, microbiologists and pharmacists. The 
surgical plan and perioperative antibiotic treatment plan was decided based upon this 
discussion. 
 
Within Northumbria Healthcare NHS Foundation Trust the majority of the planned 
revision patients undergo diagnostic synovial fluid aspiration using an effective and 
dedicated theatre list aspiration service undertaken in sterile conditions  (Tingle et al., 
2016). Subsequent microbiological culture was undertaken to identify any evidence of  
prosthetic joint infection prior to revision surgery. To optimise identification of 
infection, antibiotics were withheld for at least two weeks prior to aspiration. Routinely 
a combination of multiple deep soft tissue samples and synovial fluid were sent for 
microscopy, culture and testing for antibiotic sensitivity. Samples were sent separately 
in sterile universal containers. The samples transferred to the microbiology laboratory 
for processing. 
4.2.2 Development of standard operating procedures for collection and 
transportation of clinical samples 
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Following the identification of a suitable patient by the clinical team and successful 
recruited by the research nurse a member of the laboratory research team was informed. 
A unique study patient ID was assigned to each patient recruited, and this was used to 
identify the implant for the purposes of research. The nominated member of the 
research team arrived at the operating theatre with a pre-sterilised and dried Pathopax 
container (Pathopax DGP Intelsius Ltd 1 Harrier Court, Airfield Business Park, 
Elvington. York UK) which was used to collect and transport the samples. These were 
wrapped in two layers inner green and outer blue Suradrape (Westfield Medical Limited 
Second Avenue, Westfield Trading Estate, Midsomer Norton, Radstock, BA3 4DP) 
with autoclave marking tape. The Pathopax containers were autoclaved within 
Newcastle University; heat dried and allowed to return to room temperature before use. 
The outer blue layer was removed ensuring positive colour change from indicator tape 
and ensuring no holes in the inner green layer. Sterile gloves were applied, and the inner 
green layer opened just prior to transfer of the explanted joint prosthesis. The researcher 
stood outside of the laminar flow surgical field. Once explanted from the patient the 
implant was kept within the sterile operative field. As soon as appropriate it was passed 
out by the scrub nurse in a sterile fashion to the researcher outside of the surgical field, 
but within the laminar flow. The lid was closed and the sample was further wrapped 
and labelled with the Study ID before being placed in a transport bag for transportation 
to Newcastle University. These steps are summarised in figure 30. 
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Figure 30. Summary steps in the collection of the explanted prosthesis to ensure 
sterile transfer for subsequent processing.1) equipment required. 2) preparation for 
receiving implant and ensuring container sterility. 3) positioning of researcher for 
implant transfers. 4) transfer of implant from surgical team into sterile plastic 
container. 5) labelling of sample. 6) packing of sample for transfer. 
 
In order to ensure safe transportation, the UK Health & Safety Executive guidance was 
adopted primarily legislation UN 3373 (HSE-3373, 2016).  The Pathopax containers 
utilised complied with UN 3373 covering the packaging and transportation of 
diagnostic specimens.  The containers utilised also where CE marked confirming they 
were leak proof and complied with the EU in vitro Diagnostic Medical Devices 
Directive 98/79/EC Annex 1 B 2.1 (EU-DMDD, 2016). Once packaged the samples 
were transferred to Oral Biology Laboratory within the School of Dental Sciences at 
Newcastle University for further evaluation.  
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4.2.3 Processing of samples within the NHS.  
 
Within Northumbria Healthcare NHS Foundation Trust, standard operating procedures 
exist for the evaluation of prosthetic joint infection at the time of surgery. Routine 
practice for any revision procedure requires microbiological evaluation of the 
periprosthetic soft tissue lying close to the revised implant. Samples of soft tissue are 
harvested using a sampling set with separate instruments for each sample to avoid 
contamination, and are taken from discrete areas around the joint. Separate fluid 
samples are sent if present and often inoculated into blood culture bottles (BD 
Bactec®). About 5-7 samples were sent from each case with an average size of 1cm3. 
Samples were placed into separate sterile universal containers labelled with patient 
identifying labels and then transferred via the internal porter staff to the clinical 
microbiology laboratory.  
 
Within the laboratory, samples were processed within a class two cabinet and using 
sterile instruments used to prevent contamination.  The soft tissue samples were 
processed for routine culture and sensitivity with prior homogenisation. Within the 
sterile cabinet, large pieces of tissue were placed in a sterile petri dish and cut into 
smaller pieces. These were aseptically added to a universal container containing 1ml of 
sterile saline and glass beads using sterile disposable forceps. The sample was then 
vortexed for 15 seconds. Following this, using single individually wrapped sterile 
pipettes, the resultant fluid was drawn up and used to inoculate each agar plate (LP-
MIC-FLU-271, 2017). The agars used are summarised below and including an 
enrichment broth in the following order, and then spread with sterile loops.  
               
 
 
 
 
 
Summary of the agar growth media used for prosthetic joint sample culture within the 
NHS  
Following inoculation, the plates were placed into either aerobic or anaerobic 
incubators culture for 14 days at 37 0C. If culture positive single colonies were isolated 
for identification using the automated VITEK 2 system (bioMérieux, Marcy l’Etoile, 
France). Fluid samples that have been pre-inoculated into blood culture bottles in 
theatre were processed using the semi-automated BD Bactec® FX system (Becton 
Dickinson and Company, 1 Becton Drive Franklin Lakes, NJ USA). Samples arriving 
Robertson’s cooked meat broth 5 pipette drops (if sufficient) 
Chocolate blood agar 1 pipette drop 
Blood agar 1 pipette drop 
FAA + 5µg metronidazole disc  1 pipette drop 
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to the laboratory were loaded into the BACTEC machine which is incubated at 36 0C 
and agitated for maximum recovery or organisms. The presence of microorganisms was 
detected via an automated photo-detector which monitors a colour change to a CO2 
sensitive maker in the bottom of the BACTEC bottle. Metabolic activity of the isolated 
organisms drives the formation of CO2 prompting the detectable colour change. Positive 
cultures are flagged to the Biomedical staff who undertake the confirmation, isolation 
and identification of the organisms via VITEK 2 system. 
 
4.2.4 Processing of samples at Newcastle University  
 
Samples were transported to the Oral Biology Laboratory within Newcastle University 
for processing. Microbiological analysis was carried out in a class II cabinet, using 
aseptic technique to reduce the risk of contamination of the sample. Prior to analysis 
the cabinet was cleaned according to existing laboratory protocols. The explanted 
prostheses were processed with either NucB treatment or Non-NucB control. If a third 
sample was available this was evaluated with sonication.  
 
4.2.5 Nuclease NucB treatment of explanted prosthetic joints 
 
The reaction mixture for the NucB was prepared prior to the exposure to the explanted 
joint. Pre aliquoted 150 µl stock solutions of 100 µl/ml NucB enzyme was removed 
from -800c storage and allowed to thaw at room temperature. Prior to use 0.75 mL tris 
Buffer pH8.0 and 6.6 mL MnSO4. (Stock 100mM) and 7.5 ml sterile distilled water 
were then combined, vortexed and then brought to room temperature. The final step 
was addition of 150 µL NucB (100 µl/ml), and gently mixed giving a final reaction 
volume of 15ml. The final reaction volume equated to 5mM MnSO4 concentration 
required for for optimal NucB activity.  
 
The explanted joint prosthesis was transferred into a sterile sampling bag (Fisher 
Scientific Twirl ‘EM’ sampling bag UK Fisher Scientific Ltd Bishop Meadow Road 
Loughborough LE11 5RG) with the use of sterile gloves within the class II cabinet. The 
NucB solution was then added to the bag with excess air removed prior to sealing the 
bag.  The bag containing the explanted joint was then transferred to a tilt table at room 
temperature at 10 tilts per minute (Heidolph polymax 1040 Heidolph UK – Radleys 
Shire Hill Saffron Walden Essex, CB11 3AZ) and left for one hour.   
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The component of the explant joint replacement assigned to the non-NucB treatment 
was processed in an identical fashion using the reaction mixture listed above without 
the active addition of NucB with the residual volume reconstituted with sterile water.  
Once reconstituted, the implant was placed on the tilt table in an identical fashion.   
 
4.2.6 Sonication treatment of explanted prosthetic joints  
  
Sonication treatment was only used if there was a third component available for 
processing. This was undertaken using a modified technique based on Trampuz et al 
(2007) 400mls of pre-aliquoted and sterilised PBS solution was placed into a sterilised 
open mouthed ‘Pathopax’ container. The container was then vortex for 30 seconds 
using a Vortex-Genie 2 (Scientific Industries) before being transferred to the sonication 
bath (Engisonic Engis Ltd, Kent, UK)  for 5 minutes, followed by subsequent vortexing 
for 30 seconds. Resultant supernatants from all processes were then processed in a 
similar fashion. Then 0.5 ml aliquots were taken from each of the processed samples, 
inoculated and spread onto tryptic soy agar, blood agar, chocolate agar plates and 
fastidious anaerobic Agar (EU-DMDD, 2016).  A further 1 ml from each of the sample 
fluids was inoculated into 6mls sterile TSB, enrichment and anaerobic media.  Plates 
and liquid cultures were then labelled and sealed before being transferred for aerobic 
or anaerobic incubation (Baker Ruskinn Bugbox Plus Ruskinn Technology, Ltd. 8 & 9 
York Park Bridgend Industrial Estate, Bridgend South Wales) at 37 oC. Plates were 
checked on a daily basis for culture growth. If the cultures were positive the number of 
colony forming units were recorded and the plates reviewed by visual inspection for 
the presence of poly microbial infection. Three representative colonies were inoculated 
into the same sterile growth media as that the isolated were identified on and cultured 
for 24 hours prior to the creation of a glycerol stock which when was then stored at -80 
0C. The liquid cultures were reviewed daily for evidence of organism growth. If growth 
was suspected, 0.5ml from the liquid media was inoculated onto agar plates and 
following further incubation, representative colonies were chosen in a similar fashion 
to create a glycerol stock. Following 14 days of culture, 0.5mls of all the liquid media 
samples were inoculated onto sterile media plates and cultured for a further 24 hours. 
If there was no growth at this stage the samples were discarded. All organisms isolated 
were reconstituted onto agar slopes and transferred to Newcastle upon Tyne Hospitals 
NHS Foundation Trust Microbiology Department at Freeman Hospital for 
identification by MALDI-TOF (Carbonnelle et al., 2011). 
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4.2.7 Method to evaluate compatibility with automated NHS culture and presence of 
NucB.  
 
To evaluate the effect of NucB on the automated culture systems commonly used within 
the NHS (Minassian et al., 2014), the following experiments were undertaken using the 
Bactec® FX system (Becton Dickinson and Company, 1 Becton Drive Franklin Lakes, 
NJ USA). Clinical samples of Staphylococcus epidermidis (SE 096R) and 
Staphylococcus aureus (SA 518F) were utilised. A comparable method was used from 
chapter two (2.2.6) evaluating the effect of the presence on NucB on bacterial growth. 
The clinical isolates were established from glycerol stocks on to TSA plates and 
statically incubated overnight at 37 0C. Representative colonies were chosen and 
inoculated into 5mls of sterile TSB and again incubated overnight at 37 0C. Using a 
spectrophotometer the absorbance at 600 nm each media concentration was then 
inoculated with the re-suspended culture to create an optical density of 0.01. Having 
standardised the inoculum, 2.5 ml were transferred into sterile falcon tubes and 
incubated for 20 minutes at room temperature with and without the presence of NucB 
at a concentration of 1000 ng/ml in the presence of 5mM of MnSO4. A separate sample 
containing sterile TSB solution used for the dilution of the culture stocks was included 
with NucB processing. The final samples were inoculated into Bactec ® bottles. Culture 
bottles were pre-labelled with unique research identifiers. The cover caps were 
removed, and the injection portal cleaned with pre-impregnated ethanol wipes. Using a 
sterile needle and syringe, 5mls of the culture media was inoculated into each pre-
labelled culture bottle. Samples were gently mixed and packaged. The samples were 
transferred to Newcastle upon Tyne Hospitals NHS Foundation Trust microbiology 
department for processing according to standard NHS SMI protocols (SMI-B44, 2017).  
 
 
 
 
4.2.8 Development of a randomisation strategy for treatment of explanted joints  
 
To offer a randomised approach to the allocation of the explanted implants a 
randomisation schedule was established for both hip and knee joint replacements. This 
was developed following discussion and assistance from Mr Keith Gray a clinical 
statistician from the Research and Development department within Northumbria 
Healthcare NHS Foundation Trust.  If one sample was retrieved this was processed with 
NucB treatment. If two samples were retrieved the samples were allocated according 
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to the group randomisation table corresponding to the number of the research samples. 
If three samples were retrieved the sample that remained was allocated to sonication 
treatment. This formed a group or block randomisation strategy with the aim of dividing 
the samples available randomly while trying to provide a balance of implants allocated 
treatment protocols (Moher et al., 2012).    
 
 
4.2.9 Methods used for the identification and recruitment of participants. 
 
Patients were identified on a weekly basis if undergoing planned revision surgery for 
either a hip or knee joint arthroplasty. Potential patients were identified from the 
scheduled theatre lists by the clinical team and approached prior to surgery by a 
dedicated research nurse. Patients presenting acutely and requiring revision surgery 
were identified by the on call surgical teams during the daily trauma meetings. These 
patients were either approached by the research nursing team or a member of the 
surgical team to discuss potential participation. Patient information sheets were 
provided and patients were recruited according to Good Clinical Practice (GCP) 
guidelines (MHRA, 2017). Patients were included in the study if they were aged over 
18, were able to provide informed consent to participate and if the planned surgery 
required either exchange or removal of part of a joint arthroplasty from the hip or knee.  
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4.3 Results 
 
4.3.1 Current UK practice for diagnosis of prosthetic joint infection  
 
The current practice for the collection, transportation and processing of clinical samples 
retrieved for the diagnosis of prosthetic joint infection is covered by the UK Standards 
for Microbiology Investigations  - Investigation of orthopaedic implant associated 
infections B44 produced by Public Health England (B44, 2017). These documents were 
updated during the time period of the MD project, however no significant changes were 
made to the recommended culture methods used.  Northumbria Healthcare NHS 
Foundation Trust are compliant with the recommendations in sample processing. 
Methods used within the Trust were reviewed with the microbiology team within 
Northumbria Healthcare NHS Foundation Trust and discussed with the Consultant 
microbiology lead. Whist not identical, both sample processing with the NHS and the 
research laboratory were deemed comparable.  
 
 
4.3.2 Recruited participants and subsequent treatment analysis 
 
A total of 24 patients were recruited into the study enabling 66 separate implants to be 
evaluated. This flow diagram summarises the recruited patients and samples.  
 
 
Figure 31. Flow diagram summarising the patients screened during the study period 
and allocation to treatment. 
34 revisions
2 patients refused
2 unable to provide 
informed consent
24 patients recruited 66 implants
21 Sonication
24 + NucB 
21-NucB6 patients unable to be recruited prior to surgery 
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During the study period a total of 34 patients were screened. Two patients refused their 
consent to participate in the study, two were unable to provide informed consent and 
six patients were unable to be approached in a timely fashion prior to their surgery.  
Twenty four patients were therefore recruited allowing the processing of 66 implants 
during the study and these were divided between NucB and a non-NucB control and 
with sonication treatment if a third component of the explant joint  was available.  
 
 
 
4.3.3 Recruited participant demographics 
 
At total of 24 patients were recruited into the study. This patient group was composed 
of 14 males and 20 females. The average age at the time of revision surgery was 79 
with a range of 54-94. The American Society of Anesthesiologists (ASA) (Doyle, 2017) 
grade for each patient is presented below giving an appreciation of general health of the 
patients undergoing revision surgery. Of the patients recruited in to the study 5 were 
diabetic, 1 patient had a diagnosis of rheumatoid arthritis and three patients were active 
smokers.  
 
 
Table 6. Summary of ASA grades of patients undergoing revision surgery. 
 
(ASA) Definition 
Number 
of 
patients 
1 Normal Healthy patient 0 
2 Mild systemic disease 7 
3 Systemic disease not incapacitating  15 
4 Incapacitating disease that is a threat to life 1 
5 Moribund patient unlikely to survive > 24 hours 0 
 
 
Table 6 summarises the patient anaesthetic related score - American Society of 
Anesthesiologists (ASA). This provides a validated assessment of the patient’s 
general health at the time of surgery.  
 
 
 
 
 
4.3.4 Summary of prosthetic joints recovered and indication for revision  
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Figure 32. Summary of the prosthetic joints available from the 24 patients recruited 
 
 
Figure 32 summarises the 24 patients that provided explanted joints for evaluation. The 
majority of joint replacements were either primary hip total replacements or primary 
total knee replacements. i.e. those patients who have only had one prosthetic joint 
replacement to the index joint prior to their revision surgery. The remainder were either 
revision joint replacement surgery i.e. further surgery on a joint that has been previously 
revised or hip hemiarthroplasty which is a monoblock replacement of the femoral head 
with no prosthetic replacement to the acetabulum. These implants are frequently used 
for patients that have fractured their femoral neck following a fall. The most common 
surgical intervention for the planned revision was a single stage revision. The numbers 
of each surgery are summarised below.  
 
24 patients
7 Primary TKR
10 Primary THR
1 Revision TKR
5 Revison THR
1 Hip 
Hemiarthroplasty
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Figure 33. Summary of the interventions undertaken at the time of revision surgery  
 
 
 
Figure 34. Summary of the indication for revision surgery of recruited patients.  
 
 
 
 
 
9%
83%
8%
SURGICAL INTERVENTION 
DAIR Single stage Two stage
Wear / loosening
57%
Dislocation
13%
Established infection
30%
INDICATION FOR REVISION
Wear / loosening Dislocation Established infection
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Table 7. Summary of patients recruited into the study identifying their reason for 
revision presentation type, if the patients were on antibiotics prior to the time of their 
revision and the preoperative CRP   
 
Reason for 
revision Presentation 
Antibiotics two 
weeks prior CRP (mg/l) 
Infection  Acute no 130 
Infection  Acute no 101 
Infection  Acute yes* 106 
Infection  Chronic no 60 
Infection  Chronic no 27 
Infection  Chronic no 47 
Infection  Chronic no 55 
Wear Chronic no <5 
Wear Chronic no <5 
Wear Chronic no 6 
Wear Chronic no <5 
Wear Chronic no <5 
Wear Chronic no <5 
Wear Chronic no <5 
Wear  Chronic no 7 
Wear Chronic no <5 
Wear Chronic no 6 
Wear Chronic no <5 
Wear Chronic no <5 
Wear Chronic no not available 
Wear Chronic no <5 
Dislocation Chronic no <5 
Dislocation Chronic no <5 
Dislocation Chronic no not available 
 
 
One of the patients recruited into the study was on antibiotic therapy at the time of their 
revision surgery. This patient underwent debridement and exchange of mobile 
components for a total knee replacement (DAIR). This was processed using NucB 
exposure and gave a positive culture of Staphylococcus epidermidis  
 
In table 7 it is demonstrated that the majority of patients undergoing revision presented 
with a chronic duration with their symptoms and / or date of the index surgery being 
greater than six weeks after their revision.  All patients that underwent a planned 
revision procedure for established infection met the MSIS major criteria for infection. 
The majority of patients did not have an elevated C-reactive protein (CRP). In the case 
of 2 patients recruited into the study a CRP value was unavailable. All patients that 
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underwent a revision surgical procedure for suspected infection had a significantly 
elevated CRP. While the remaining were mildly elevated or normal CRP levels below 
the MSIS minor diagnostic criteria threshold of  >10 mg/l (Deirmengian et al., 2014). 
 
4.3.5 Summary of clinical isolates recovered 
 
Table 8. Summary of the clinical organism identified from the research samples 
 
Isolates recovered Number of isolates 
Bacteria (gram positive)  
Staphylococcus warneri 1 
Streptococcus dysgalactiae 1 
Staphylococcus epidermidis 4* 
S. aureus, methicillin - sensitive (MSSA) 1 
Enterococcus faecalis 1 
Fungal  
Candida albicans 1 
 
* A total of 8 infected cases were identified however, one case was a 
polymicrobial infection of Candida albicans and Staphylococcus epidermidis 
 
Table 8 summaries the organisms that were obtained from the research samples. The 
majority of these were Staphylococcus epidermidis. No gram-negative organism were 
identified. One sample was identified as a fungal organism. 
 
4.3.6 Comparison of NucB compared to sonication for identification of biofilm 
encapsulated bacteria from explanted prosthetic implant surfaces 
 
Of the 24 patients that were available for evaluation it was possible to isolate organisms 
from 8 patients using either + NucB, – NucB or sonication.  The remaining 18 patients 
explanted implant surfaces were negative on all culture techniques matching the 
standard NHS results. When comparing the standard NHS techniques for the processing 
of infected samples within Northumbria NHS Foundation Trust and the NucB or 
sonication techniques used within this study, there were no samples with a positive 
culture from the NHS diagnosis that were not detected by either NucB or sonication 
treatment.  
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4.3.7 Review of the culture positive cases comparing NHS and Research 
samples  
 
 
 
 
 
Figure 35. Summary of the number of culture positive cases recruited into the study 
 
 
4.3.8 Comparison of clinical isolates identified from explanted joints prosthesis 
to NHS clinical data.  
 
Table 9. Comparison of the research and the NHS positive culture results obtained 
from explanted joints  
 
Infected 
sample 
Research result 
NucB  
Research result 
Sonication  
Time to 
result 
NHS Result Time to 
Result 
1 Streptococcus  
dysgalactiae 
Streptococcus  
dysgalactiae 
< 24 Streptococcus  
dysgalactiae 
72  
2 Staphylococcus 
epidermidis 
Staphylococcus 
epidermidis 
< 24 Staphylococcus 
epidermidis 
48 
3 Staphylococcus 
warneri 
Staphylococcus 
warneri 
24-48 Not isolated n/a 
4 Candida Candida < 24 Candida 48 
4 Staphylococcus 
epidermidis 
Staphylococcus 
epidermidis 
< 24 Not isolated n/a 
5 Staphylococcus 
epidermidis 
Staphylococcus 
epidermidis 
< 24 Staphylococcus 
epidermidis 
72 
6 Staphylococcus 
aureus, 
methicillin - 
sensitive (MSSA) 
Staphylococcus 
aureus, 
methicillin - 
sensitive (MSSA) 
< 24 Staphylococcus 
aureus, methicillin - 
sensitive (MSSA) 
48 
7 Staphylococcus 
epidermidis 
Staphylococcus 
epidermidis 
< 24 Staphylococcus 
epidermidis 
72 
8 Enterococcus 
faecalis 
 
Enterococcus 
faecalis  
<24  Enterococcus 
faecalis 
24-48 
 
 
24 patients
8 positive cultures
16 negative cultures
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Table 9 summarises the bacteria identified from the explanted joints using NucB and 
sonication treatment compared to the NHS sampling techniques. Overall there was high 
concordance from the research results compared to the NHS samples. The majority of 
cases only a single organism was identified in both the clinical and laboratory 
investigations. Sample 4 appeared to be a polymicrobial infection with both Candida 
albicans and Staphylococcus epidermidis present. Sample 3 was found to contain 
Staphylococcus warneri, which was not detected using traditional NHS diagnostic 
processes.  No other variations were identified.  
 
 
 
 
Infected 
sample 
Causative 
organism 
identified in the 
laboratory 
NucB 
 cfu/ml 
NucB 
control 
cfu/ml 
Sonication  
cfu/ml 
A
ntibiotics  
CRP  
Presentation 
1 Streptococcus  
dysgalactiae 
414 n/a n/a N 130 acute 
2 Staphylococcus 
epidermidis 
624 90 444 N 27 chronic 
3 Staphylococcus 
Warneri 
54 0 58 N 7 chronic 
4 Candida albicans  n/a n/a n/a N 101 acute 
4 Staphylococcus 
epidermidis 
92 n/a n/a N 101 acute 
5 Staphylococcus 
epidermidis 
212 n/a n/a Y 106 acute 
6 Staphylococcus 
aureus, 
methicillin - 
sensitive (MSSA) 
286 0 204 N 60 chronic 
7 Staphylococcus 
epidermidis 
730 90 810 N 47 chronic 
8 Enterococcus 
faecalis  
909 74 610 N 55 chronic 
 
Where an implant was not available for analysis N/A was recorded. In sample 4, CFU 
could not be counted for the fungal infection. 
 
Table 10 summaries the results from the infected samples comparing the CFU/ml 
obtained. When multiple plates of different culture media were positive for the same 
Table 10. Summary of the organisms identified and the CFU/ml from each technique. 
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sample the plate with the largest number of colonies were recorded for comparison. 
This was always the same plate culture medium for each prosthetic joint replacement, 
independent of which media was utilised. Sonication samples and NucB positive 
samples results were comparable for all prosthetic components. Samples 7 and 8 
recorded positive results from the NucB control.  Sample 3 and 4 revealed organisms 
from sonication and NucB but not from the NucB control. No variations were seen 
between the ultimate culture media or technique utilised and the final organism 
identified. In general, where sonication treatment was possible, NucB treatment 
released the most bacterial cells as indicated by cfu data. Although in some samples 
sonication gave slightly higher colony counts. In all cases, the NucB controls where no 
enzyme was used gave significantly lower colony counts indicating the efficacy of 
NucB in releasing viable cells from clinical samples. 
 
 
Table 11 Summary of discordant results obtained from NHS processed samples and 
laboratory processed samples 
 
 
 
 
Discordant results summarised in the above table were identified on two occasions. 
Sample 3 was a planned revision for acetabular wear and lysis from a total hip 
replacement. Preoperatively there were no concerns regarding infection based on the 
standardised preoperative evaluation of combined clinical assessment and joint 
aspiration. However, both sonication and NucB mediated processing of separate 
explanted components identified Staphylococcus warneri  as being present This finding 
would have influenced patient care in terms of follow up and possible use of antibiotic 
therapy as the revision was undertaken as a single stage due to the absence in the 
suspicion for infection.  Sample 4 demonstrated a poly- microbial infection as identified 
by the NucB and sonication treated samples. The standard culture techniques identified 
Infected 
sample 
Research result  
NucB  
Research result  
Sonication 
Reason 
for 
revision 
Implant 
revised 
CRP Presentation 
type 
3 Staphylococcus 
warneri 
Staphylococcus 
warneri 
Wear Primary 
THR 
6 Chronic 
4 Candida albicans Candida albicans Infection Revision 
THR 
101 acute 
4 Staphylococcus 
epidermidis 
Staphylococcus 
epidermidis 
Infection Revision 
THR 
101 acute 
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an isolated Candida albicans infection. This case was recognised clinically as an 
infected case and underwent a two stage revision. The presence of Staphylococcus 
epidermidis was not detected using the standard NHS protocols. This again would have 
influenced patient management in terms of antibiotic therapy. The results given above, 
while carried out on relatively small numbers of samples, provide an early indication 
that a NucB mediated process appears to help in the diagnosis of infection and the 
identification of the causative organism in a manner which is better than current 
microbiological practice. Therefore, the ease of incorporation of NucB mediated 
diagnostic protocols into NHS standard practice was investigated. 
 
 
4.3.9 Potential integration of NucB protocols to aid in the diagnosis of infection 
from explanted joint prosthesis within UK current practice. 
 
 
To evaluate the potential for NucB to be incorporated into the automated BD Bactec® 
FX system routinely used for the processing of PJI microbiological specimens a 
simulated sample with a known inoculum and causative organism was utilised with 
appropriate control. This is summarised in the table below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
Table 9. Summarised culture results from the automated culture system used within 
the NHS with and without the presence of NucB.  
 
Sample Culture report 
Provisional 
report 
available 
Final report 
Staphylococcus 
epidermidis - NucB 
Staphylococcus 
epidermidis < 24 hours 
Staphylococcus 
epidermidis 
Staphylococcus 
epidermidis + NucB 
Staphylococcus 
epidermidis < 24 hours 
Staphylococcus 
epidermidis 
Sterile TSB + NucB No growth  < 24 hours No growth  
Staphylococcus 
aureus - NucB 
Staphylococcus 
aureus < 24 hours 
Staphylococcus 
aureus 
Staphylococcus 
aureus + NucB 
Staphylococcus 
aureus < 24 hours 
Staphylococcus 
aureus 
Sterile TSB + NucB No growth  < 24 hours No growth  
 
 
The results of the experiment to evaluate the effect of the presence of NucB on the 
automated BD Bactec ® FX system. In all cases for both isolates the inoculated 
organism matched the final cultured organism. There was no difference in the timing 
of results obtained. Cultures results for negative inoculation were negative for growth 
as expected. While the presence of the Nuclease NucB would not be expected to restrict 
the processing of the culture sample within the automated system. The CO2 sensitive 
disc at the base of the culture bottle may have been susceptible to the novel enzyme 
NucB, this however was not demonstrated.  
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4.3.10 Proposed clinical application of a closed sampling system incorporating 
NucB 
 
 
 
 
 
 
Figure 36. diagram of proposed intra operative sampling of explanted joint prosthesis 
and incorporation into NHS standard microbiology processing 1) joint explanted from 
patient 2) explanted joint placed into sealed bag containing NucB solution 3) 
following a period of exposure, fluid is transferred to culture bottle and sent to lab for 
standard processing.  
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Figure 37. Proposed sampling system including sampling bag, example of explanted 
hip prosthesis and NucB solution with culture bottle.  A) Culture Bactec ®  bottle. B) 
NucB solution. C) Sterile processing bag with connection for culture bottle. D) 
explanted joint prosthesis.  
 
 
 
Figures 36 and 37 summarise the proposed use of NucB in the clinical setting. This was 
not evaluated as part of the study but provides a foundation for future work 
incorporating NucB treatment into the NHS standard clinical diagnostic procedures 
summarised in Figure 38 below.  
 
A 
C 
B 
D 
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Figure 38. Flow diagram demonstration the standard NHS processing (SMI-B44, 
2017) and the possible incorporation of NucB solution on the explanted joint.  
 
These results indicate that NucB can be usefully applied to increase the release of viable 
bacterial cells from biofilm attached the explanted joint and that this appears to provide 
some advantage over standard practice in the diagnosis of PJI. Standard tissue samples 
and synovial fluid sampling undertaken at the time of surgery may be augmented by 
evaluation of the explanted joint which is currently often discarded. Sonication requires 
further processing and often awkward or time consuming steps. Use of a NucB solution 
within a receiving bag lowers the risk of contamination while utilising the explanted 
joint as a source of further information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revison surgery 
Tissue Samples
Transfer to 
Laboratoy for 
further 
processing
Await culture 
results
Synovial fluid 
sample 
Await culture 
results
Sonication
Transfer to 
Laboratoy for 
further 
processing
Await culture 
results
NucB 
innoculation into 
culture bottle
Await culture 
results
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4.5 Discussion  
 
4.1.1. Techniques in the diagnosis of PJI 
 
Having evaluated the use of NucB in the removal of biofilm encapsulated bacteria on  
simulated prosthetic joint surfaces in Chapter 3, the clinical evaluation and pilot study 
into the potential effectiveness of NucB on explanted joint prosthesis from clinical 
patients undergoing revision surgery was undertaken. Initial work aimed to evaluate 
and compare the current practices and standards set out for the evaluation of 
microbiology samples sent at the time of revision arthroplasty surgery within the NHS 
and in particular Northumbria Healthcare NHS Foundation Trust. Site visits were 
undertaken to the microbiology department to evaluate the current practice and 
compare these to the proposed methods of processing explanted joints.  Northumbria 
Healthcare NHS Foundation Trust like all accredited Trusts follow guidance which is 
summarised within the methods and results section. The microbiology facilities at 
Newcastle University while not accredited by Public Health England followed similar 
practices when handling clinical samples, making results comparable between the two 
laboratories during study period.  Even with the guidance on offer to UK Hospitals via 
the UK Standards for Microbiology Investigations (SMIs) variation in actual protocols 
used does exist (Arciola et al., 2011, Hansen et al., 2012, Larsen et al., 2012). This is 
related to local skill mix and availability of equipment and is driven by the need to 
target harder to culture organisms such as Propionibacterium acnes (Butler-Wu et al., 
2011). All Trusts nevertheless, would be expected to provide standard culture 
procedures and determination of antibiotic sensitivities of bacteria isolated from tissue 
and fluid from around the joint. However, there is provision within the standards for 
further evaluation to be undertaken within the microbiology department. For example 
synovial white cell counts (Ghanem et al., 2008, Dinneen et al., 2013), MALDI-TOF 
mass spectrometry (Carbonnelle et al., 2011) or PCR (Lambert et al., 1996, Espy et al., 
2006) to provide additional information. Outside the United Kingdom, further 
challenges exist in the processing of samples and subsequent comparisons (Societe de 
Pathologie Infectieuse de Langue et al., 2010, Osmon et al., 2013b) For the purposes 
of this clinical study comparison was made between the results from the standard 
culture processing undertaken with Northumbria Healthcare NHS Foundation Trust and 
the processing carried out within the Oral Biology Laboratory within the School of 
Dental Sciences at Newcastle University 
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4.1.2. Challenges with transportation and compliance with regulations  
 
The recommended culture techniques and the requirements for collection, 
transportation and processing of clinical samples were guided by stringent regulations. 
This forms part of the compliance and governance stipulations for the transportation of 
clinical samples within the UK: 
 
“European Parliament. UK Standards for Microbiology Investigations (SMIs) use the 
term "CE marked leak proof container" to describe containers bearing the CE marking 
used for the collection and transport of clinical specimens. The requirements for 
specimen containers are given in the EU via Diagnostic Medical Devices Directive 
(98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, 
where necessary, reduce as far as possible contamination of, and leakage from, the 
device during use and, in the case of specimen receptacles, the risk of contamination 
of the specimen. The manufacturing processes must be appropriate for these 
purposes".  
 
In order to follow this legislation, the subsequent sourcing and validation of an 
acceptable container for transport of an explanted prosthesis proved to be a significant 
challenge. The containers not only had to meet the standards set out by several UK 
governing bodies but had to be suitable in size and shape in order to adequately 
accommodate the prosthesis. To avoid excessive cost, they were required to be 
autoclaved for reuse. Following discussion with microbiology departments around 
Europe regarding their choice of bottles for sonication there seemed to be no consensus 
(M Marsh data not shown). The published literature often does not mention which 
containers are used (Sebastian et al., 2018) or have used “lock and lock” containers 
more commonly used in food storage and are not CE marked for clinical samples or 
documented leak proof.  Some centres have been using sterile bags for the 
transportation and processing of samples. The bags often have wider mouths and so can 
accommodate implants without the limitations often seen in bottles (Esteban et al., 
2008). However, this practice is now concerning due to the potential leakage of bags 
and a subsequent risk of contamination, especially since the large volume of water used 
for the sonication has previously been a concern regarding potential water 
contamination within the microbiology department and the production of aerosols 
during sonication treatment. This risk was first highlighted by Trampuz et al, one of 
the early adopters of sonication of the explanted implant (Trampuz et al., 2006).  
To overcome the challenges posed by the processing and transportation of clinical 
samples, studies often exclude implants that they cannot transport because they are too 
large (Van Diek et al., 2017, Erivan et al., 2018). This practice was evident throughout 
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the literature, however, was not encountered during this study. This is a significant 
limitation of any technique that requires the transportation of the implant with larger 
implants very often being excluded from evaluation. Larger implants those extending 
into the diaphyseal region of long bones are often encountered in revision surgery 
(Barry et al., 2017) or with endoprosthetic replacement used for bone malignancy 
(Hardes et al., 2010). Patients who are immunocompromised as a result of treatment 
for malignancy or patients undergoing multiple revision surgeries have increased 
susceptibility to infection and consequently, have an even greater need for the timely 
and accurate diagnosis of existing infection. However, due to the size of their explanted 
joint they may not be put forward for evaluation and therefore may not benefit from 
analysis of the explanted joint. This clinical study did not have to exclude any samples 
due to their size related to transportation or processing. Some larger implants including 
a longer stem femoral component were recruited into the study but no endoprosthetic 
replacements.  
 
4.1.3. Review of patients recruited into the study 
 
Two patients were unable to provide informed consent to participate and could 
therefore not be included in the study (figure 31). This is a limitation of the study design 
based upon ethical approval requirements. Patients without capacity are more likely to 
be trauma patients requiring revision surgery for a peri-prosthetic fracture which is a 
common injury seen following a fall. Impairment of capacity can also be caused by co-
existing delirium as a direct consequence of acute sepsis from prosthetic joint infection. 
These patients are often at higher risk of complications, including infection, due to their 
unplanned surgery and lack of preoperative medical optimisation (Zmistowski et al., 
2013). A presumed consent model including consultation with an appropriate consultee 
would have allowed inclusion of these patients into the study. This model already has 
a precedent within orthopaedic trials (Sims et al., 2016). However, this model is more 
suited to larger randomised studies rather than the initial evaluation of a novel concept 
such as the role of NucB in the diagnosis of PJI. Six patients were not approached in a 
timely fashion prior to surgery to enable inclusion in the study. This was a consequence 
of limited research support and availability to facilitate the recruitment and consent of 
participants. This patient group may represent patients requiring more urgent revision 
surgery rather than planned revision surgery and will again cause a degree of bias in 
the patients recruited.  Due to the inclusion criteria only, hip and knee joint 
replacements were eligible for recruitment. These joints represent the greatest volume 
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of revision joint replacements on the National Joint Registry (NJR, 2017), there was a 
mix of both primary and revision joint replacements for evaluation. Revision surgical 
procedures are at greater risk of infection a consequence of the indicative number of 
procedures previously  to the joint and effects on the surrounding soft tissue envelope 
health (Mortazavi et al., 2010). The inclusion of both primary and revision procedures 
in this cohort strengthens the results and  reflects the case mix presented by the National 
Joint Registry  as well as other clinical studies evaluating the effectiveness of other 
techniques to increase the bacterial yield from explanted joint prosthesis (Drago et al., 
2012, Liu et al., 2017a) 
 
The patient demographics followed a similar pattern to those presented within the data 
provided by the National Joint Registry. The average age for revision for hip or knee 
replacement surgery nationally for any cause was 71 years of age. There was a slight 
predominance of female to male of 56% to 44% nationally.  The majority of patients 
from the national  data were ASA grade 2 or 3 at the time of surgery (NJR, 2017).  The 
recruited cohort of patients into this study had a similar female predominance as the 
national data, with a slightly higher average age of 79 and ASA.  Nevertheless, this 
smaller cohort matched the national spread relating to patients requiring revision 
surgery. Indication for revision surgery was summarised in figure 33 and 34 the 
majority of cases were for wear or loosening, with the next largest group for established 
infection. The National Joint Registry again publishes the indication for revision 
surgery (NJR, 2017). This is separated into hip and knee revisions with further 
subdivision of the indication for revision. Infection as the indication for hip revision 
was 14% of single stage revision and 81% of two stage revisions. Loosening of the joint 
accounted for 60 % of single stage revisions and around 18% for two stage revisions. 
There were slightly higher numbers of revisions for infection for total knee 
replacements within the national data.  There were no revisions for pain within this 
cohort. Depending on the joint revised this equates to around 12 % of revision surgery 
according to the National Joint Registry.  Overall the small cohort of patients recruited 
into this study reflected the national trend well, in the indication for revision and 
planned surgical procedures suggesting there was no significant bias in the type of 
patients recruited.  
 
Table 7 summaries the presentation type in terms of chronicity and the presence of 
antibiotics within the last two weeks as well as the patient’s inflammatory markers. 
Elevation of peripheral blood C – reactive protein (CRP) is a marker of infection 
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(Berbari et al., 2010) however, CRP is also raised in any pro inflammatory condition 
(Lindqvist et al., 2005). It forms part of the standard assessment of patients suspected 
of prosthetic joint infection as well as one of the diagnostic criteria of infection (Parvizi 
et al., 2011a, Osmon et al., 2013a, Parvizi et al., 2014). C- reactive protein is highly 
sensitive but not specific for prosthetic joint infection. A value > 10 mg/l has been 
associated with a 96% sensitivity, a 92% specificity, a 74% positive predictive value 
and a 99% negative predictive value (Berbari et al., 2010). It can however be close to 
normal limits in chronic low grade prosthetic joint infection (Spangehl, 2016). C - 
reactive protein can be elevated with infection elsewhere and also in patients with non-
infected inflammatory conditions such as rheumatoid arthritis. The majority of patients 
within this study with confirmed infection were those presenting acutely and had 
elevated C-reactive protein levels just prior to revision.  In this situation, there is less 
of a clinical dilemma regarding the diagnosis of infection and identification of the 
causative organism is less of a diagnostic challenge (Della Valle et al., 2010). This 
however, can be confounded by the presence of antibiotics given close to the time of 
revision. The early evaluation of sonication by Trampuz et al demonstrated that 
sonication of the explanted implant was most beneficial for patients that had been on 
antibiotics within two weeks of the revision (Trampuz et al., 2007) when comparing 
tissue culture to sonication. Sonicate fluid culture was more sensitive than tissue culture 
75% vs. 45%, P<0.001 respectively when antimicrobial agents were discontinued 
within 14 days of surgery. This finding demonstrated the benefit of sonication within 
this subset. The positive conclusion of this early work resulted in a change in standard 
practice within the UK and an education programme for general practitioners and 
hospital doctors regarding the effect of giving antibiotics in suspected prosthetic joint 
infection cases, if the patient is clinically well (Osmon et al., 2013a). The resultant 
change to standard practice ensured an antibiotic free window prior to aspiration. This 
was also standard practice for the Northumbria Healthcare NHS Foundation Trust and 
as a result only one patient was on antibiotics at the time of surgery (table 7). This 
patient presented clinically unwell with systemic signs of infection with antibiotics 
given prior to revision surgery to ensure timely and necessary treatment for a septic 
patient. In this case there was no diagnostic challenge in identifying the causative 
organism most likely due to the high bacterial load and the short interval between the 
commencement of antibiotics and surgery (less than 24 hours). The increasing 
awareness of sepsis via a World Health Organization initiative and developed by the 
Department of Health, may result in a justified shift back to the prescribing of 
antibiotics to potentially septic patients prior to aspiration (Reinhart et al., 2017). This 
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may result in an increase in the number of patients that have been started on antibiotics 
prior to their revision surgery thus making subsequent identification of the causative 
organism more challenging. This step would mean that a technique that can improve 
diagnosis of an infected explanted joint would be increasingly beneficial. 
 
4.1.4. Organisms isolated from the explanted joint prosthesis  
 
The most frequently isolated causative organism was Staphylococcus – most 
commonly Staphylococcus epidermidis and Staphylococcus aureus (Table 8). These 
causative organisms are recognised at the most common for implant associated 
infections  (Trampuz and Zimmerli, 2005, Moran et al., 2007, Peel et al., 2012) and 
therefore formed the majority of the work undertaken on the pre-clinical evaluation of 
NucB in the previous chapters. Enterococcus faecalis was isolated as a causative 
organism for one case of prosthetic joint infection.  Although rarer, Enterococcus 
faecalis represents around 3% of all infections and yearly rates have been increasing 
(Tornero et al., 2014b). These cases are more challenging to treat due to their greater 
antibiotic resistance (Tornero and Soriano, 2015, Lopez-Sanchez et al., 2016). 
Enterococcus faecalis is known to use eDNA as a fundamental element in its biofilm 
matrix (Thomas et al., 2008). In a similar manner to Staphylococcus aureus studies 
have demonstrated that Enterococcus faecalis uses  a fratricidal signalling pathway for 
the release of eDNA in the  formation of its biofilm (Thomas et al., 2009). Enterococcus 
faecalis biofilm sensitivity to NucB was not evaluated in the simulated model of 
prosthetic joint infection but the reliance of eDNA in the biofilm matrix would suggest 
that NucB would have a strong theoretical target on which to act.  
In one case a Candida albicans infection was identified. Fungal infections are known 
causal agents in prosthetic joint infection and again rarer than other organisms more 
commonly encountered (Cuellar-Cruz et al., 2012). Candida albicans PJI forms a 
significant challenge requiring a long duration of antifungal medication, which is often 
poorly tolerated by the patient (Phelan et al., 2002).  Additionally, revision surgery for 
Candida albicans infection has a higher failure rate (Reddy et al., 2013). eDNA also, 
plays an important role in Candida albicans biofilm formation (Martins et al., 2010, 
Costa-Orlandi et al., 2017). No gram-negative bacteria were isolated during the study 
period. These organisms are a rarer cause of prosthetic joint infection and make up 
between 9-25 percent of all infections (Hsieh et al., 2009). The more common gram-
negative infections are due to Escherichia coli, Pseudomonas aeruginosa and 
Klebsiella pneumonia are also known to utilise eDNA as an important component of 
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their biofilms (Whitchurch et al., 2002, Zhao et al., 2013, Alcantar-Curiel et al., 2013) 
with Pseudomonas aeruginosa being one of the first organisms with an identified 
susceptibility to nuclease action (Allesen-Holm et al., 2006) and therefore have a likely 
predisposition to nuclease degradation. While the use of NucB or sonication may not 
have been required to identify the causal agent in all of the explanted components (table 
10) all of the isolates that were recovered have demonstrated have the potential for 
nuclease degradation via the presence of eDNA within the biofilm matrix. 
 
 
4.1.5. Comparison between NHS results and results from experimental samples 
 
When comparing the infection positive results obtained from the research samples and 
the standard NHS sampling there was a high level of concordance. This is similar to 
the majority of study results reviewing outcomes from sonication, overall the majority 
of samples correlated to the clinical results (Zhai et al., 2014). An early study with 
sonication recruited 404 patients comparing sonication and standard culture techniques 
- of these 12 patients had discordant results (Trampuz and Zimmerli, 2005).  Within the 
cohort evaluated in the work of this thesis, 2 patients had discordant results from the 24 
patients recruited (table 11). These discordant positive results between the standard 
NHS healthcare setting and the research results indicate the potential value of 
examining the explanted joint to aid diagnosis of infection. No discordance was seen 
however, between the samples processed by NucB and Sonication (table 9) 
demonstrating that within this cohort NucB was just as successful, as a new technique, 
at detecting a causative organism. Given the low total numbers of participants, 
calculations of the sensitivity and specificity between sonication and NucB would be 
unreliable. However, if the findings within this cohort are correct, evaluation of the 
explanted joint would have resulted in a change to the further management of 2 patients. 
In some instances, NucB was no more effective than the non-NucB control in releasing 
CFU (table 10, samples 2,7 and 8. These cases were seen in acute infections where 
there was likely a high bacterial count (Martínez-Pastor et al., 2009). The mechanical 
effect of the tilt table in samples with a control solution not containing NucB would 
likely have dislodged bacteria physically coating the explant, though possibly not 
necessarily encapsulated on the implant surface. This could be considered a similar 
process to scraping the implant surface to release bacteria. This technique is not 
routinely undertaken given its historical low yield (Bjerkan et al., 2009). This was seen 
in the non-NucB control in 2 samples and could be similar to the lower ‘background’ 
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readings seen in the non-NucB samples in chapter 3. Comparing the CFU/ml in table 
10 provides an indication of the effectiveness of each diagnostic approach to the 
explanted joint.  The variability in the size of implants, the different materials used and 
different surface roughnesses of the implants, all of which have been shown to affect 
bacterial biofilm adhesion (Teughels et al., 2006, Rochford et al., 2012, Veerachamy et 
al., 2014) makes direct comparison challenging. Nevertheless, dividing the samples 
between techniques allowed approximate comparison of the techniques used. There 
were 5 patients where 3 components were available. Here NucB and sonication 
produced comparable CFU while the non-NucB control produced fewer CFU 
suggesting that NucB and sonication were both cable of increasing the yield of bacteria 
from the explanted joints.   
 
Reviewing the discordant results summarised in table 11 Staphylococcus warneri was 
identified from the research samples using NucB and sonication to dislodge cells but 
not from the standard NHS microbiologcal methods. This species is a coagulase-
negative staphylococcus and is a normal skin commensal (Nagase et al., 2002). While 
not the most common cause, Staphylococcus warneri has demonstrated pathogenicity 
as has been shown to be the causal agent in prosthetic joint infection (Arciola et al., 
2005). Staphylococcus warneri infection similar to Staphylococcus epidermidis 
infection, is considered a less virulent organism but is known to be able to form biofilms 
on prosthetic implant surfaces (Campoccia et al., 2010). The presence of poly microbial  
infection in PJI is increasing and provides a significant surgical challenge with greater 
rates of failure following revision (Wimmer et al., 2015). This is related to increased 
antibiotic resistance with a synergistic increase in biofilm formation being 
demonstrated by both of the causal organims (Pammi et al., 2013). Pammi et al 
evaluated the importance of eDNA in the synergistic formation of Staphylococcus 
epidermidis and Candida albicans biofilms in implant associated infection. This 
combination was also identified within this work with both NucB treatment and 
sonication (table 11)  
Sonication has been demonstrated to increase the detection of polymicromial infections 
(Janz et al., 2015).  Janz et al in a series of 109 patients undergoing revision surgery for 
TKR identified a polymicrobial infection in 29% of cases however, 50% of the 
polymicrobial isolations were only diagnosed using the sonicated fluid. This outcome 
maybe related to the presence of a dominant species within the polymicrobial infection 
and a more sessile species that forms a polymicrobial biofilm community on the 
prosthetic implant surface. Standard tissue culture or aspiration may therefore fail to 
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readily detect the second causative organism that remains dormant on the implant 
surface. Thus it can also be postulated that the use of NucB provides an additional 
technique with which to reveal polymicrobial infections that are not readily observed 
using traditional microbiological diagnostics. 
 
4.1.6. Comparison between techniques available to increase the yield of viable     
bacteria from infected surfaces 
 
Comparison between techniques undertaken to evaluate the explanted joint remain 
difficult. The largest controversy affecting the comparison of techniques remains the 
sonication method and the accepted cut-off for the CFU count which is accepted as 
representing confirmed infection. The original cuff off was 5 cfu/ml/plate based on 0.5 
ml inoculation with 400 mls of fluid vortexing and no concentration step by 
centrifugation (Trampuz et al., 2007). However, a large variation remains principally 
surrounding the amount of fluid used and the inclusion of the vortexing step. Some 
techniques advocating covering the implant in sonication buffer fluid (Vergidis et al., 
2011). Depending on the size of the implant this can introduce large variations. This 
also further depends on the implant and container used. A meta-analysis of 12 studies 
evaluating sonication suggested from subgroup analyses that the use of centrifugation 
or vortexing and 400–500 mL sonication solution may improve sensitivity and or 
specificity respectively with the best cut-off of ≥5 colony-forming units (Zhai et al., 
2014). The meta-analysis did not evaluate the sonication energy levels or the containers 
used and it was also unable to review the cases that were excluded from all studies due 
to the size of the implant or contamination. These are all important factors that would 
have influenced results. These attempts to generate a cut-off of colony forming units 
are aimed at reducing false positive results, which may occur most likely from 
contamination during processing.  
 
The cohort of patient samples used in this work showed a wide variation in colony 
forming units/ml.  Using the established cut off 5 CFU/plate for sonication there were 
no patients that would have been classed below the level of possible contamination 
(Due to the volume of inoculant 10 cfu/ml equates to 5 cfu/plate used by Trampuz et 
al). Given the challenges with sonication and a validated CFU number, several studies 
have now adopted the use of culture bottle evaluation of the sonicated fluid (Larsen et 
al., 2012, Portillo et al., 2015). This moves away from the CFU number with blood 
bottle culture and theoretically reduces the risk of contamination. However, this 
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technique may increase the false positive rate as it is not possible to quantify the initial 
bacterial inoculation and thus provide a cut off.  
Since the NucB technique is novel there is currently no guidance available on to 
establish a cut-off, recruitment of further patients would provide this further 
information to guide a cut off level.   
 
Direct comparison regarding the time to positive culture between the NHS and research 
samples cannot be performed since they were processed by varying methods. Nearly 
all the samples showed positive growth under 24 hours on plates. The majority of 
samples within the NHS were available within 2-7 days. These are only released once 
formally approved by the microbiology department and therefore the results are 
susceptible to possible delay. There was no difference in time to culture between the 
components exposed to either sonication or NucB.  Whilst formal comparison cannot 
be undertaken theoretically a technique that releases biofilm encapsulated bacteria and 
stimulates the conversion from a dormant slowly dividing cell to a more active 
planktonic form is recognised by Costerton et al  (Costerton et al., 1978). These faster 
diving cells should allow for the earlier detection by microbiological culture-based 
methods. Earlier detection would improve patient care by commencing antibiotic 
treatment or following identification allowing their earlier rationalisation to optimise 
treatment (Osmon et al., 2013b).  
 
 
4.1.7. Integration of NucB techniques into standard NHS diagnostics practice 
 
The final studies were undertaken to determine if NucB processing of explanted joints 
could potentially be incorporated effectively into current NHS practice (table 12). 
Evaluation of the use of automated culture bottle techniques demonstrated 
compatibility. Such techniques have already been evaluated with the use of sonication 
fluid from explanted joints in two studies (Shen et al., 2015, Portillo et al., 2015). In 
both studies sonication fluid inoculated into culture bottles demonstrated higher 
sensitivity and specificity than standard tissue culture techniques.  With Patel et al 
demonstrating improved sensitivities when comparing synovial fluid cultures in Bactec 
® bottles and sonication fluid cultured in Bactec ® bottles with sensitivities of 64% 
and 88%, respectively (P = 0.009). The use of the Bactec ® bottles in the UK for the 
evaluation of prosthetic joint infection has recently been recognised as an accepted 
culture method (B44, 2017). However, as previously discussed the sonication technique 
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requires the transportation and processing of the explanted joint within a laboratory. 
The process requires the handling and transfer as well risk of fluid leak and 
contamination. This has been recognised with several studies demonstrating low levels 
of <5 CFU/plate being routinely cultured and designated as contamination (Trampuz et 
al., 2007, Puig-Verdie et al., 2013). To eliminate the need for transfer and allow prompt 
processing of the implant NucB solution could be used in theatre as soon as the implant 
is explanted (figures 36 and 37) This limits the risk of contamination due to minimal 
changes of receptacle and allows processing to be undertaken in the sterile environment 
of theatre. Further advantages are the minimal time delay in the processing of the 
sample before inoculation into culture medium (Van Cauter et al., 2018). This is of 
significant benefit with low grade infections caused by fastidious bacteria such as 
Propionibacterium acnes and has the potential to improve identification of causal 
organism (Shah et al., 2015). This technique for the processing of samples within a 
“closed” system has subsequently been developed using DTT and is currently 
undergoing clinical evaluation (Drago et al., 2012, Sambri et al., 2018). The use of DTT 
was not evaluated in this work but is the subject of future studies by this research team. 
 
 
4.6 Conclusions 
 
Overall this study has demonstrated that the treatment of samples with the nuclease 
NucB has shown high concordance in terms of identification of causative organisms 
compared to standard microbiological methods, suggesting a low false positive rate. 
NucB treatment was equally as effective as sonication and both methods identified the 
presence of pathogens not revealed by standard methods that would likely have 
influenced patient care. This underlines the importance for diagnosis of dislodging 
bacteria from biofilms prior to diagnosis. NucB demonstrated the ability to release 
causal organisms from a greater number of species including Candida albicans not 
evaluated in the first two chapters confirming the wider potential of NucB in the 
diagnosis of PJI. No benefit was observed in the diagnosis of acute infections where 
standard culture techniques were able to confirm PJI. The use of NucB appeared to be 
compatible with current NHS culture techniques and therefore has the potential for 
seamless incorporation into standard practice. However, this research study is only an 
initial validation of the effectiveness of NucB in the diagnosis of prosthetic joint 
infection. It has been undertaken with small numbers of patients and further recruitment 
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of patients in larger numbers will be required in order to confirm the suggested increase 
in sensitivity and specificity of this method. 
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4 Chapter 5 Overall discussion and conclusions 
 
 
The solution to the diagnosis of orthopaedic implant associated infection remains 
elusive and may never be fully realised. Examination of the explanted joint has the 
potential to provide additional information to assist in the diagnosis of PJI. eDNA is 
now recognised as an essential part of the biofilm matrix. The nuclease NucB via its 
action on eDNA has proven a novel and effective method to release encapsulated 
bacteria, thereby aiding in the diagnosis of infection. The effect of NucB on clinical 
isolates has been shown to be comparable to its effect on reference strains and clinical 
isolates of the most commonly encountered causal bacteria. These results are largely 
comparable to sonication on a simulated implant model and to the clinically explanted 
joint replacements recruited into this study. Within the clinical series presented, the 
exposure of the explanted joint to either NucB or sonication improved detection of 
causal agents by the identification of a causal organism, which was not simultaneously 
detected using standard NHS culture techniques. Furthermore, NucB enabled 
identification of a second less dominant organism in a poly-microbial infection; that 
was also not detected by standard techniques. The true merit of NucB in future clinical 
practice, remains to be fully realised, due the varying processing techniques involved 
and a need for more samples. Utilisation of this enzyme could facilitate the diagnostic 
processing of samples from explanted joints which may provide a faster culture 
diagnosis. In addition to this, a timely diagnosis would enable earlier rationalisation of 
antibiotics and an overall improvement in patient care.  
 
The study of bacterial biofilms, remains challenging due to inherent variances in the 
models utilised between different experimental techniques and clinical isolates used. In 
essence this means direct comparison between techniques is impossible. (Carli et al., 
2016).  An additional complexity is the lack of standardised definition of infection to 
which diagnostic tests are compared. A universal consensus regarding this definition 
would aid in the comparison of clinical research. The recommendation for the use of 
clinical isolates having been recruited from prosthetic joint infection improves the 
model methodology however, makes further comparison between studies more 
challenging (Fux et al., 2005). The creation of reference strains for clinical orthopaedic 
infection models and the standardisation of a model in which to evaluate novel agents 
may in the future improve comparison and aid in future research. 
This work focused on the exogenous use of NucB to release biofilm encapsulated 
bacteria. However, it should be recognised that a similar action could be achieved by 
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the up-regulation and release of endogenous nucleases present within the bacterial 
biofilm. Such approaches have been investigated and the production of nucleases has 
been demonstrated to be tightly regulated and related to virulence (Olson et al., 2013) 
and appears to be under control of several distinct pathways. For example, for 
Staphylococcus aureus, sigma factor B has been identified as a potential trigger for 
nuclease release (Kiedrowski et al., 2011, Schulthess et al., 2011). Whilst increasing 
expression of endogenous nuclease may prove effective it is likely that it will only 
provide a solution for its own biofilm disruption and not those of other bacteria. This 
therefore may require a tailored target for each bacterium and would not provide a 
solution as a diagnostic tool. This approach would also be limited by the significant 
cost implications. Currently the most effective way to utilise the action of nucleases is 
via an exogenous source. NucB is effective at releasing viable cells from an 
encapsulated biomass and its use in prosthetic joint infection is comparable to the 
natural role this nuclease has evolved over time.  Utilisation of this is natural biofilm 
dispersing ability of NucB is both promising and inviting. The initial experiments 
undertaken in this study have demonstrated its efficacy and suitability to provide a 
promising adjunct to the diagnosis of prosthetic joint infection.  
 
However, evaluation of the effectiveness of NucB within this piece of research has a 
number of limitations. The initial in-vitro studies undertaken in chapters two and three 
utilise an accepted model previously employed for biofilm dispersal. However, these 
models could not reproduce the clinical and mechanical environment of the joint or the 
effect of a host immune response. Both of these factors would influence biofilm 
formation and is a recognised weakness of in-vitro models (Roberts et al., 2015). 
Animal models would have provided a closer simulation and may prove helpful in the 
further evaluation of the effectiveness of NucB in future studies. Whilst the pilot 
clinical study made use of the actual clinical challenge for which NucB effectiveness 
was evaluated, variation between the explanted joints and between patients made 
comparison more challenging.  
 
 
 
Dividing the implants between NucB, NucB control and sonication meant significant 
variation existed between the surface area and implant material that could not be 
resolved. Undertaking this division did confirm that occasionally for the non NucB ie 
the control sample the causal organism could be identified. This incorporation of a 
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control is rarely included in other clinical studies where comparisons are made solely 
with the standard techniques, commonly tissue cultures specimens (Drago et al., 2012, 
Erivan et al., 2018). These patients often had acute infections where the evaluation of 
the explanted joint by any means would not have been beneficial since standard culture 
techniques were able to identify the causal organism anyway.  This similar outcome 
been seen demonstrated in other studies evaluating sonication (Puig-Verdie et al., 
2013). Another limitation of this study is the number of patient samples analysed; 
recruitment of a greater number of patients would have improved the ability to compare 
results. However, fortunately infection is a relatively rare event. Additionally, the 
exclusion of patients that were unable to provide informed consent meant that they 
could not be incorporated into the study. It is likely that these patients would have 
benefited to a great extent from the evaluation of the explanted joint since these patients 
often presented to hospital acutely as a result of infection and may have already been 
given antibiotics.  In future research, this patient group could be included by adopting 
a presumed consent model which is now more frequently used in clinical research. This 
recruitment model would include this interesting patient group and subsequently have 
the potential to provide an insight into the effectiveness of NucB in these more 
challenging cases. 
 
Another challenge is the complexity associated with using enzyme technology. The 
marine nuclease NucB whilst effective within the laboratory setting has the 
disadvantages common to the use of enzyme based technology in clinical practice. This 
is primarily a formulation issue of the enzyme, there are several examples,  of enzymes 
being utilised commercially to reduce biofilm formation (Augustin et al., 2004, 
Lequette et al., 2010). Other techniques to increase the yield of explanted joints would 
not have similar issues (Drago et al., 2012).  However, the marine nuclease NucB is 
currently the most suitable nuclease available in terms of effectiveness, ease of 
production and cost (Nijland et al., 2010, Basle et al., 2018).  
 
 
NucB processing of the explanted joint was evaluated for incorporation into the 
standard NHS diagnostic pathway. Like other techniques such as sonication (Liu et al., 
2017a) and DTT (Drago et al., 2013) NucB was comparable. However, like all of these 
techniques the interpretation of the results remains the greatest challenge. The emphasis 
placed on a positive culture result from the explanted joint should likely form part of 
the assessments available to diagnose PJI. The mainstay of diagnosis will rest with 
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clinical examination and investigations as part of a multi-disciplinary approach. 
Incorporating all culture results from the explanted joint treated with NucB into an 
algorithm taking all clinical information into consideration will be needed to provide a 
positive predictive calculation to improve the accuracy of diagnosis. This approach is 
currently being evaluated by Gallazzi et al, who are developing a combined diagnostic 
tool (Gallazzi et al., 2017).  
 
In summary microbiological examination of the explanted joint for the presence of 
infection is a valuable tool in the diagnosis of infection. Since infectious agents are not 
always revealed by traditional methods which has significant implications for surgical 
decisions and the NHS as a whole. This work for the first time has evaluated a novel 
enzymatic approach to assist in the diagnosis of PJI.  NucB appears to be effective at 
releasing biofilm encapsulated bacteria under both laboratory and clinical settings and 
has demonstrated comparable efficacy with sonication without many of the recognised 
disadvantages. These initial promising findings should be more thoroughly explored 
with a larger clinical trial to develop and evaluate further the effectiveness of NucB as 
a diagnostic adjunct, thus improving the diagnosis of PJI, which currently remains one 
of the most challenging complications in orthopaedic surgery. 
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